Table of Contents
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Quarter Ended November 26, 2017,February 28, 2021, or

[  ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition period for _________ to _________.

Commission file number: 0-27446

LANDEC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

94-3025618

 (StateDelaware

94-3025618
(State or other jurisdiction of incorporation or organization)

 (IRS(IRS Employer Identification Number)

5201 Great America Parkway, Suite 232

Santa Clara, California 95054


2811 Airpark Drive
Santa Maria,California93455
(Address of principal executive offices)(Zip Code)

(650) 306-1650
(Address of principal executive offices)

Registrant's telephone number, including area code:

(650) 306-1650

code)


Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock

stock, par value $0.001 per share

LNDC

The NASDAQ Global Select Stock Market

Securities registered pursuant to Section 12(g) of the Act:

None

(Title of Class)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beenbeen subject to such filing requirements for the past 90 days. Yes   X    No ___


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   X    No ___

Indicate by check mark whether the registrant is a large acceleratedaccelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitionthe definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer       ___     Accelerated Filer  X   ☒Emerging Growth Company
Non Accelerated Filer          ___     Smaller Reporting Company ___
Emerging Growth Company ___ ☐

If an emerging growth company, indicate by check mark if the registrantregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ___

Indicate by check mark whether the registrant is a shell companycompany (as defined in Rule 12b-2 of the Exchange Act). Yes ___ No    X  

As of December 21, 2017,April 6, 2021, there were 27,533,89229,332,832 shares of Common Stockcommon stock outstanding.






Table of Contents


LANDEC CORPORATION

FORM 10-Q

For

For the Fiscal Quarter Ended November 26, 2017

February 28, 2021


INDEX

Page

Page

Facing sheet

Index

i

d)

4

e)

5

18

26

26

27

27

27

27

27

27

27

28

29


i

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

LANDEC CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

  

November 26, 2017

  

May 28, 2017

 
  

(unaudited)

     

ASSETS

        

Current Assets:

        

Cash and cash equivalents

 $4,369  $5,409 

Accounts receivable, less allowance for doubtful accounts

  56,356   47,083 

Inventories

  30,836   25,290 

Prepaid expenses and other current assets

  4,426   3,498 

Total Current Assets

  95,987   81,280 
         

Investment in non-public company, fair value

  65,800   63,600 

Property and equipment, net

  135,271   133,220 

Goodwill

  54,779   54,779 

Trademarks/tradenames, net

  16,028   16,028 

Customer relationships, net

  6,291   6,783 

Other assets

  5,152   2,918 

Total Assets

 $379,308  $358,608 
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current Liabilities:

        

Accounts payable

 $37,483  $25,868 

Accrued compensation

  7,624   8,211 

Other accrued liabilities

  8,471   9,125 

Deferred revenue

  1,673   310 

Line of credit

  10,000   3,000 

Current portion of long-term debt

  4,940   4,940 

Total Current Liabilities

  70,191   51,454 
         

Long-term debt

  39,829   42,299 

Capital lease obligation, less current portion

  3,688   3,731 

Deferred taxes, net

  26,028   24,581 

Other non-current liabilities

  6,863   8,391 

Total Liabilities

  146,599   130,456 
         

Stockholders’ Equity:

        

Common stock, $0.001 par value; 50,000 shares authorized; 27,534 and 27,499 shares issued and outstanding at November 26, 2017 and May 28, 2017, respectively

  28   27 

Additional paid-in capital

  143,490   141,680 

Retained earnings

  87,103   84,470 

Accumulated other comprehensive income

  568   432 

Total Stockholders’ Equity

  231,189   226,609 

Non-controlling interest

  1,520   1,543 

Total Equity

  232,709   228,152 

Total Liabilities and Stockholders’ Equity

 $379,308  $358,608 

value)

February 28, 2021May 31, 2020
(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents$2,248 $360 
Accounts receivable, less allowance for credit losses69,577 76,206 
Inventories76,779 66,311 
Prepaid expenses and other current assets14,323 14,230 
Total Current Assets162,927 157,107 
Investment in non-public company, fair value45,100 56,900 
Property and equipment, net168,693 192,338 
Operating leases23,528 25,321 
Goodwill69,386 69,386 
Trademarks/tradenames, net25,328 25,328 
Customer relationships, net11,288 12,777 
Other assets3,573 2,156 
Total Assets$509,823 $541,313 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable$56,323 $51,647 
Accrued compensation11,218 9,034 
Other accrued liabilities11,186 9,978 
Current portion of lease liabilities4,027 4,423 
Deferred revenue1,595 352 
Line of credit41,000 77,400 
Current portion of long-term debt, net11,554 
Total Current Liabilities125,349 164,388 
Long-term debt, net145,051 101,363 
Long-term lease liabilities24,430 26,378 
Deferred taxes, net6,608 13,588 
Other non-current liabilities3,761 4,552 
Total Liabilities305,199 310,269 
Stockholders’ Equity:
Common stock, $0.001 par value; 50,000 shares authorized; 29,323 and 29,224 shares issued and outstanding at February 28, 2021 and May 31, 2020, respectively29 29 
Additional paid-in capital164,865 162,578 
Retained earnings41,446 71,245 
Accumulated other comprehensive loss(1,716)(2,808)
Total Stockholders’ Equity204,624 231,044 
Total Liabilities and Stockholders’ Equity$509,823 $541,313 

See accompanying notes.

notes to the consolidated financial statements.
-1-

Table of Contents

LANDEC CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(Unaudited)

(In thousands, exceptexcept per share amounts)

  

Three Months Ended

  

Six Months Ended

 
  

November 26,

2017

  

November 27,

2016

  

November 26,

2017

  

November 27,

2016

 

Product sales

 $136,457  $135,865  $259,814  $268,259 
                 

Cost of product sales

  120,705   116,912   224,776   228,162 
                 

Gross profit

  15,752   18,953   35,038   40,097 
                 

Operating expenses:

                

Research and development

  3,372   1,965   6,091   3,903 

Selling, general and administrative

  12,934   13,724   26,979   27,460 

Total operating costs and expenses

  16,306   15,689   33,070   31,363 
                 

Operating (loss) income

  (554

)

  3,264   1,968   8,734 
                 

Dividend income

  412   412   825   825 

Interest income

  42   4   74   7 

Interest expense

  (480

)

  (380

)

  (884

)

  (1,032

)

Loss on debt refinancing

     (1,233

)

     (1,233

)

Other income

  1,300      2,200    

Net income before taxes

  720   2,067   4,183   7,301 

Income tax expense

  (207

)

  (693

)

  (1,458

)

  (2,582

)

Consolidated net income

  513   1,374   2,725   4,719 

Non-controlling interest expense

  (26

)

  (48

)

  (92

)

  (81

)

Net income applicable to common stockholders

 $487  $1,326  $2,633  $4,638 
                 

Basic net income per share

 $0.02  $0.05  $0.10  $0.17 

Diluted net income per share

 $0.02  $0.05  $0.09  $0.17 
                 

Shares used in per share computation

                

Basic

  27,518   27,249   27,512   27,234 

Diluted

  27,875   27,618   27,866   27,572 
                 

Other comprehensive income, net of tax:

                

Change in net unrealized gains on interest rate swap (net of tax effect of $140, $192, $85, and $192)

 $239  $327  $136  $327 

Other comprehensive income, net of tax

  239   327   136   327 

Total comprehensive income

 $726  $1,653  $2,769  $4,965 


Three Months EndedNine Months Ended
February 28, 2021February 23, 2020February 28, 2021February 23, 2020
Product sales
$137,782 $152,928 $404,328 $434,235 
Cost of product sales
118,093 132,881 347,657 383,338 
Gross profit19,689 20,047 56,671 50,897 
Operating costs and expenses:
Research and development2,562 2,747 7,643 8,390 
Selling, general and administrative15,220 18,783 49,227 54,000 
Legal settlement charge1,763 
Restructuring costs2,700 13,528 12,766 13,934 
Total operating costs and expenses20,482 35,058 71,399 76,324 
Operating loss(793)(15,011)(14,728)(25,427)
Dividend income281 281 844 843 
Interest income13 46 31 96 
Interest expense, net(4,178)(2,211)(10,326)(6,455)
Loss on debt refinancing(1,110)(1,110)
Other income (expense), net72 67 (11,736)61 
Net loss before tax(5,715)(16,828)(37,025)(30,882)
Income tax benefit217 5,310 7,226 7,840 
Net loss$(5,498)$(11,518)$(29,799)$(23,042)
Net loss per common share:
Basic$(0.19)$(0.39)$(1.02)$(0.79)
Diluted$(0.19)$(0.39)$(1.02)$(0.79)
Shares used in per share computation:
Basic29,323 29,170 29,282 29,155 
Diluted29,323 29,170 29,282 29,155 
Other comprehensive income (loss), net of tax:
Net unrealized gain (loss) on interest rate swaps (net of tax effect of $(99), $124, $(327), and $305)$387 $(411)$1,092 $(896)
Other comprehensive income (loss), net of tax387 (411)1,092 (896)
Total comprehensive loss$(5,111)$(11,929)$(28,707)$(23,938)

See accompanying notes.

notes to the consolidated financial statements.
-2-

Table of Contents

LANDEC CORPORATION

CONSOLIDATED STATEMENT OF CHANGES INSTOCKHOLDERS’ EQUITY

(Unaudited)

(inIn thousands, except per share amounts)

  

Common Stock

  

Additional

Paid-in

  

Retained

  

Accumulated Other

Comprehensive

  

Total

Stockholders’

  

Non-controlling

 
  

Shares

  

Amount

  Capital  Earnings  Income  Equity  Interest 

Balance at May 28, 2017

  27,499  $27  $141,680  $84,470  $432  $226,609  $1,543 

Issuance of common stock at $5.63 to $6.66 per share, net of taxes paid by Landec on behalf of employees

  1                   

Issuance of common stock for vested restricted stock units (“RSUs”)

  34   1            1    

Taxes paid by Company for employee stock plans

        (256

)

        (256

)

   

Stock-based compensation

        2,066         2,066    

Payments to non-controlling interest

                          (115

)

Net income

           2,633      2,633   92 

Other comprehensive income, net of tax

              136   136    

Balance at November 26, 2017

  27,534  $28  $143,490  $87,103  $568  $231,189  $1,520 

See accompanying notes.


Three and Nine Months Ended February 28, 2021
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
 Loss
Total
Stockholders’
Equity
Common Stock
SharesAmount
Balance at May 31, 202029,224 $29 $162,578 $71,245 $(2,808)$231,044 
Issuance of stock under stock plans18 — — — — 
Taxes paid by Company for employee stock plans— — (82)— — (82)
Stock-based compensation— — 892 — — 892 
Net loss— — — (11,000)— (11,000)
Other comprehensive income, net of tax— — — — 304 304 
Balance at August 30, 202029,242 29 163,388 60,245 (2,504)221,158 
Issuance of stock under stock plans81 — — — — 
Taxes paid by Company for employee stock plans— — (215)— — (215)
Stock-based compensation— — 895 — — 895 
Net loss— — — (13,301)— (13,301)
Other comprehensive income, net of tax— — — — 401 401 
Balance at November 29, 202029,323 29 164,068 46,944 (2,103)208,938 
Stock-based compensation— — 797 — — 797 
Net loss— — — (5,498)— (5,498)
Other comprehensive income, net of tax— — — — 387 387 
Balance at February 28, 202129,323 $29 $164,865 $41,446 $(1,716)$204,624 

-3-

Table of Contents

LANDEC CORPORATION

Consolidated StatementS of Cash Flows

(Unaudited)

(In thousands)

  

Six Months Ended

 
  

November 26,

2017

  

November 27,

2016

 

Cash flows from operating activities:

        

Consolidated net income

 $2,725  $4,719 

Adjustments to reconcile net income to net cash provided by operating activities:

        

Depreciation and amortization

  5,934   5,110 

Stock-based compensation expense

  2,066   1,773 

Deferred taxes

  1,364   2,317 

Loss on early debt extinguishment

     1,233 

Change in investment in non-public company, fair value

  (2,200

)

   

Net (gain) loss on disposal of property and equipment

  (45

)

  57 

Changes in current assets and current liabilities:

        

Accounts receivable, net

  (9,273

)

  (3,603

)

Inventories

  (5,546

)

  (2,435

)

Prepaid expenses and other current assets

  (904

)

  666 

Accounts payable

  11,615   (4,990

)

Accrued compensation

  (497

)

  236 

Other accrued liabilities

  (2,272

)

  802 

Deferred revenue

  1,363   (358

)

Net cash provided by operating activities

  4,330   5,527 
         

Cash flows from investing activities:

        

Purchases of property and equipment

  (7,431

)

  (4,738

)

Issuance of note receivable

  (2,099

)

   

Proceeds from sales of fixed assets

  73   14 

Net cash used in investing activities

  (9,457

)

  (4,724

)

         

Cash flows from financing activities:

        

Proceeds from sale of common stock

  1   193 

Taxes paid by Company for employee stock plans

  (256

)

  (272

)

Proceeds from long-term debt

     50,000 

Payments on long-term debt

  (2,543

)

  (54,697

)

Proceeds from lines of credit

  14,500   1,500 

Payments on lines of credit

  (7,500

)

  (3,500

)

Payments for debt issuance costs

     (897

)

Payments for early debt extinguishment penalties

     (233

)

Payments to non-controlling interest

  (115

)

  (166

)

Other, net

     (59

)

Net cash provided by (used in) financing activities

  4,087   (8,131

)

Net decrease in cash and cash equivalents

  (1,040

)

  (7,328

)

Cash and cash equivalents at beginning of period

  5,409   9,894 

Cash and cash equivalents at end of period

 $4,369  $2,566 

Three and Nine Months Ended February 23, 2020
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Stockholders’
Equity
Common Stock
SharesAmount
Balance at May 26, 201929,102$29 $160,341 $109,710 $64 $270,144 
   ASC 842 transition adjustment(274)(274)
   Issuance of stock under stock plans440
   Taxes paid by Company for employee stock plans(55)(55)
  Stock-based compensation528528
   Net loss(4,784)(4,784)
   Other comprehensive loss, net of tax(612)(612)
Balance at August 25, 201929,14629 160,814 104,652 (548)264,947 
   Issuance of stock under stock plans173030
   Taxes paid by Company for employee stock plans(75)(75)
  Stock-based compensation787787
   Net loss(6,740)(6,740)
   Other comprehensive income, net of tax127127
Balance at November 24, 201929,16329 161,556 97,912 (421)259,076 
   Issuance of stock under stock plans190
   Taxes paid by Company for employee stock plans(45)(45)
  Stock-based compensation566566
   Net loss(11,518)(11,518)
   Other comprehensive loss, net of tax(411)(411)
Balance at February 23, 202029,182$29 $162,077 $86,394 $(832)$247,668 

See accompanying notes.

notes to the consolidated financial statements.
-4-

Table of Contents

LANDEC CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Nine Months Ended
February 28, 2021February 23, 2020
Cash flows from operating activities:
Consolidated net loss(29,799)(23,042)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation, amortization of intangibles, debt costs, and right-of-use assets14,808 13,800 
Loss on debt refinancing1,110 
Stock-based compensation expense2,584 1,881 
Provision (benefit) for expected credit losses451 (225)
Deferred taxes(7,307)(7,881)
Change in investment in non-public company, fair value11,800 (200)
Net loss on disposal of property and equipment held and used39 135 
Loss on disposal of property and equipment related to restructuring, net7,881 11,518 
Other, net(12)139 
Pacific Harvest note receivable reserve1,202 
Change in contingent consideration liability(500)
Changes in current assets and current liabilities:
Accounts receivable, net6,178 27 
Inventories(10,468)(12,927)
Prepaid expenses and other current assets350 551 
Accounts payable6,372 11,791 
Accrued compensation2,184 (2,230)
Other accrued liabilities3,186 1,504 
Deferred revenue1,243 119 
Net cash provided by (used in) operating activities10,600 (4,338)
Cash flows from investing activities:
Proceeds from sales of property and equipment12,885 2,432 
Purchases of property and equipment(11,383)(22,118)
Proceeds from collections of notes receivable364 
Net cash provided by (used in) investing activities1,502 (19,322)
Cash flows from financing activities:
Proceeds from long term debt150,000 27,500 
Payments on lines of credit(119,400)(77,900)
Payments on long-term debt(114,095)(8,094)
Proceeds from lines of credit83,000 84,400 
Payments for debt issuance costs(9,615)(766)
Taxes paid by Company for employee stock plans(297)(175)
Proceeds from sale of common stock30 
Net cash (used in) provided by financing activities(10,407)24,995 
Net increase in cash and cash equivalents1,695 1,335 
Cash and cash equivalents, beginning of period553 1,465 
Cash and cash equivalents, end of period$2,248 $2,800 
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment on trade vendor credit$1,124 $1,793 

See accompanying notes to the consolidated financial statements.
-5-

Table of Contents
LANDEC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.

Organization, Basis of Presentation, and Summary of Significant Accounting Policies


1.    Organization,

Basis of Presentation,and Summary of Significant Accounting Policies

Organization
Landec Corporation and its subsidiaries (“Landec” or the “Company”) design, develop, manufacture, and sell differentiated products for food and biomaterials markets, and license technology applications to partners. The Company has two proprietary polymer technology platforms: 1) Intelimer® polymers, and 2) hyaluronan (“HA”) biopolymers. The Company sells specialty packaged branded Eat Smart® and GreenLine® and private label fresh-cut vegetables and whole produce to retailers, club stores, and foodservice operators, primarily in the United States, Canada, and Asia through its Apio, Inc. (“Apio”) subsidiary, and sells HA-based and non-HA biomaterials through its
Landec’s biomedical company, Lifecore Biomedical, Inc. (“Lifecore”) subsidiary. The Company’s HA biopolymers, is a fully integrated contract development and non-HA materialsmanufacturing organization (“CDMO”) that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. Lifecore recognizes revenue in two different product categories: CDMO and Fermentation.
Landec’s natural food company, Curation Foods, Inc. (“Curation Foods”) is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay packaging technology. Its products are proprietarysold in that they are specially formulated for specific customers to meet strict regulatory requirements. Through its O Olive Oil, Inc. (“O Olive”) division, which the Company acquired on March 1, 2017, the Company sells premier California specialty olive oils and wine vinegars under the O brand to natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.

The Company’s technologies, along with its customer relationshipscompany categorizes revenue in three categories, Fresh packaged salads and tradenames,vegetables, Avocado Products, and Technology which reports revenues for BreatheWay patented supply chain solutions. Included in the Curation Foods segment and fresh packaged salads and vegetables revenue disaggregation is O Olive Oil & Vinegar (“O”), which is a premier producer of California specialty olive oils and wine vinegars. Also included in the Curation Foods segment are the foundationdividends from, and key differentiating advantages upon which Landec has built its business.

Landec’s share of the change in the fair market value of the Company’s 26.9% investment ownership, of Windset, a leading edge grower of hydroponically grown produce.

Basis of Presentation

Presentation

The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with United States generally accepted accounting principlesU.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position of the Company at November 26, 2017February 28, 2021, and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with GAAP have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission.Commission (the “SEC”). The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form 10-K for the fiscal year ended May 28, 2017.

31, 2020 (the “Annual Report”).

The Company’s fiscal year is the 52- or 53-week period that ends on the last Sunday of May with quarters within each year ending on the last Sunday of August, November, and February; however, in instances where the last Sunday would result in a quarter being 12-weeks in length, the Company’s policy is to extend that quarter to the following Sunday. A 14th week is included in the fiscal year every five or six years to realign the Company’s fiscal quarters with calendar quarters.
The results of operations for the sixnine months ended November 26, 2017February 28, 2021 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in Apio’s food business, particularly, Apio’s exportCuration Foods’ business and the order patterns of Lifecore’s customers which may lead to significant fluctuations in Landec’s quarterly results of operations.

Basis of Consolidation

The consolidated financial statements are presented on the accrual basis of accounting in accordance with GAAP and include the accounts of Landec Corporation and its subsidiaries, ApioCuration Foods and Lifecore. All intercompanyinter-company transactions and balances have been eliminated.

Arrangements that are not controlled through voting or similar rights are reviewed under the guidance for variable interest entities (“VIEs”). A company is required to consolidate the assets, liabilities, and operations of a VIE if it is determined to be the primary beneficiary of the VIE.

-6-

Table of Contents
An entity is a VIE and subject to consolidation, if by design: a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support provided by any party,parties, including equity holders, or b) as a group the holders of the equity investment at risk lack any one of the following three characteristics: (i) the power, through voting rights or similar rights to direct the activities of an entity that most significantly impact the entity’s economic performance, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity. The Company reviewed the consolidation guidance and concluded that its partnership interest in Apio Cooling, LP and itsthe equity investment in the non-public company areis not VIEs.

a VIE.
-5-

Table of Contents

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; allowance for sales returns and allowances; inventories; self-insurance liabilities;credit losses; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets includingasset (including intangible assets;assets), and inventory; the valuation of investments; and the valuation and recognition of stock-based compensation and contingent liabilities.

compensation.

These estimates involve the consideration of complex factorsfactors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management’s estimates.


Cash and Cash Equivalents

The Company records all highly liquid securities with three months or less from date of purchase to maturity as cash equivalents. Cash equivalents consist mainly of money market funds. The market value of cash equivalents approximatesapproximates their historical cost given their short-term nature.

Reconciliation of Cash and Cash Equivalents as presented on the Statements of Cash Flows
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows:

(In thousands)February 28, 2021May 31, 2020February 23, 2020May 26, 2019
Cash and cash equivalents$2,248 $360 $2,607 $1,080 
Restricted cash193 193 385 
Cash, cash equivalents and restricted cash$2,248 $553 $2,800$1,465 

The Company was required to maintain $0.0 million and $0.2 million of restricted cash at February 28, 2021 and May 31, 2020, respectively, related to certain collateral requirements for obligations under its workers' compensation programs. The restricted cash is included in Other assets in the Company’s accompanying Consolidated Balance Sheets.

Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consist of the following (in thousands):

  

November 26, 2017

  

May 28, 2017

 

Raw materials

 $13,229  $10,158 

Work in progress

  4,702   3,447 

Finished goods

  12,905   11,685 

Total

 $30,836  $25,290 

following:


(In thousands)February 28, 2021May 31, 2020
Finished goods$41,533 $35,177 
Raw materials26,855 25,856 
Work in progress8,391 5,278 
Total$76,779 $66,311 

If the cost of the inventories exceeds their net realizable value, provisions are recorded currently to reduce them to net realizable value. The Company also records a provision for slow moving and obsolete inventories based on the estimate of demand for its products.


-7-

Table of Contents
Accounts Receivable, Sales Returns, and Allowance for Credit Losses
The Company carries its accounts receivable at their face amounts less an allowance for estimated sales returns and credit losses. Sales return allowances are estimated based on historical sales return amounts.
The Company uses the loss rate method to estimate its expected credit losses on trade accounts receivable and contract assets. In order to estimate expected credit losses, the Company assessed recent historical experience, current economic conditions and any reasonable and supportable forecasts to identify risk characteristics that are shared within the financial asset. These risk characteristics are then used to bifurcate the loss rate method into risk pools. The risk pools were determined based on the industries in which the Company operates. Historical credit loss for each risk pool is then applied to the current period aging as presented in the identified risk pools to determine the needed reserve allowance. At times when there are not current economic conditions or forecasts that may affect future credit losses, the Company has determined that recent historical experience provide the best basis for estimating credit losses.
The information obtained from assessing historical experience, current economic conditions and reasonable and supportable forecasts were used to identify risk characteristics that can affect future credit loss experience. There were no significant risk characteristics identified in the review of historical experiences or in the review of estimates of current economic conditions and forecasts.
Estimating credit losses based on risk characteristics requires significant judgment by management. Significant judgments include, but are not limited to: assessing current economic conditions and the extent to which they are relevant to the existing characteristics of the Company’s financial assets, the estimated life of financial assets, and the level of reliance on historical experience in light of economic conditions. The Company will continually review and update, when necessary, its historical risk characteristics that are meaningful to estimating credit losses, any new risk characteristics that arise in the natural course of business, and the estimated life of its financial assets.
The changes in the Company’s allowance for sales returns and credit losses are summarized in the following table (in thousands):
Balance at beginning of periodProvisions for expected credit lossesWrite offs, net of recoveriesBalance at end of period
Nine months ended February 28, 2021$438 $451 $(607)$282 

Related Party Transactions

The Company sells productsand licenses its BreatheWay® food packaging technology to and earns license fees from Windset Holdings 2010 Ltd. ("Windset"(“Windset”)., in which, as further described in Note 2, the Company has a 26.9% ownership interest. During the three months ended November 26, 2017February 28, 2021 and November 27, 2016,February 23, 2020, the Company recognized revenues of $91,000$0.2 million and $75,000,$0.2 million, respectively. During the sixnine months ended November 26, 2017February 28, 2021 and November 27, 2016,February 23, 2020, the Company recognized revenues of $195,000$0.4 million and $193,000,$0.4 million, respectively. These amounts have been included in productProduct sales in the accompanying Consolidated Statements of Comprehensive (Loss) Income. The related receivable balances of $109,000$0.2 million and $388,000$0.5 million are included in accountsAccounts receivable in the accompanying Consolidated Balance Sheets as of November 26, 2017February 28, 2021 and May 28, 2017,31, 2020, respectively.

All related party transactions are monitored quarterly by the Company and approved by the Audit Committee of the Board of Directors.

Debt Issuance Costs

The Company records its line of credit debt issuance costs as an asset, and as such, $120,000$0.6 million and $338,000$2.3 million were recorded as prepaidPrepaid expenses and other current assets, and otherOther assets in the accompanying Consolidated Balance Sheets, respectively, as of November 26, 2017,February 28, 2021, and $120,000$0.3 million and $399,000,$0.5 million, respectively, as of May 28, 2017.31, 2020. The Company records its term debt issuance costs as a contra-liability, and as such, $60,000$1.3 million and $171,000 was$5.0 million were recorded as currentCurrent portion of long-term debt, and long-termLong-term debt, net in the accompanying Consolidated Balance Sheets, respectively, as of November 26, 2017February 28, 2021 and $60,000$0.4 million and $201,000,$0.6 million, respectively, as of May 28, 2017.31, 2020. See Note 7 –6 - Debt offor additional disclosure related to our debt refinancing that closed on December 31, 2020 and the Notes to Consolidated Financial Statements for further information.

related impact on debt issuance costs.
-6-
-8-

Table of Contents

Financial Instruments

The Company’sCompany’s financial instruments are primarily composed of commercial-term trade payables, grower advances, notes receivable, debt instruments and debtderivative instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt and lines of credit approximates itstheir carrying value.

Cash Flow Hedges

The Company has entered into an interest rate swap agreementagreements to manage interest rate risk. ThisThese derivative instrumentinstruments may offset a portion of the changes in interest expense. The Company designates thisthese derivative instrumentinstruments as a cash flow hedge.hedges. The Company accounts for its derivative instrumentinstruments as either an asset or a liability and carries itthem at fair value in Other assets or Other non-current liabilities. The accounting for changes in the fair value of the derivative instrument depends on the intended use of the derivative instrument and the resulting designation.

For derivative instruments that hedge the exposure to variability in expected future cash flows thatand are designated as cash flow hedges, the effective portionentire change in the fair value of the gain or loss on the derivativehedging instrument is reportedrecorded as a component of Accumulated Other Comprehensive Incomeother comprehensive loss (“AOCL”) in Stockholders’ Equity andEquity. Those amounts are subsequently reclassified intoto earnings in the same period or periods during whichline item in the Consolidated Statements of Comprehensive (Loss) Income as impacted by the hedged transactionitem when the hedged item affects earnings. The ineffective portion of the gain or loss on the derivative instrument, if any, is recognized in earnings in the current period. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions.

During the third quarter of fiscal year 2021, the Company discontinued their hedge accounting prospectively since it was determined that the derivatives are no longer highly effective in offsetting changes in the net investment. The derivatives continue to be carried at fair value in the accompanying Consolidated Balance Sheets with changes in their fair values from the date of discontinued hedge accounting recognized in current period earnings in Other Income (Expense) in the Consolidated Statements of Comprehensive (Loss) Income. Amounts previously accumulated in AOCL during the period of effectiveness will continue to be realized over the remaining term of the underlying forecasted debt payments as a component of AOCL in Stockholders’ Equity.
AccumulatedOther Comprehensive Income

Loss

Comprehensive income (loss) consists of two components, net incomeloss and Other Comprehensive Incomecomprehensive income (loss) (“OCI”). OCI refers to revenue, expenses, and gains and losses that under GAAP are recorded as a component of stockholders’ equity but are excluded from net income.loss. The Company’s OCI consists of net deferred gains and losses on its interest rate swap derivative instrument accounted for as a cash flow hedge.instrument. The components of OCI and the changes in accumulated OCI,AOCL, net of tax, are as follows (in thousands):

  

Unrealized Gains on

Cash Flow Hedge

 

Accumulated OCI, net, as of May 28, 2017

 $432 

Other comprehensive income before reclassifications, net of tax effect

  136 

Amounts reclassified from OCI

   

Accumulated OCI, net, as of November 26, 2017

 $568 

follows:


(In thousands)AOCL
Balance as of May 31, 2020$(2,808)
Other comprehensive loss before reclassifications, net of tax effect(344)
Amounts reclassified from OCI1,436 
Other comprehensive income, net$1,092 
Balance as of February 28, 2021$(1,716)

The Company does not expect any transactions or other eventsexpects to occur that would result in the reclassification of any significant gains or lossesreclassify approximately $1.4 million into earnings in the next 12 months.

Investment in Non-Public Company

On FebruaryFebruary 15, 2011, the Company made its initial investment in Windset which is reported as an investmentInvestment in non-public company, fair value, in the accompanying Consolidated Balance Sheets as of November 26, 2017February 28, 2021 and May 28, 2017.31, 2020. The Company has elected to account for its investment in Windset under the fair value option. See Note 32 – Investment in Non-public Company, for further information.

-9-

Table of Contents
Assets Held for Sale
In January 2020, the Company decided to divest Curation Foods’ salad dressing plant in Ontario, California (“Ontario”). In the third quarter of fiscal year 2020, the Company (1) designated the fixed assets of its office and manufacturing space located in Ontario, California, as assets held for sale, and (2) recognized a $10.9 million impairment loss. The remaining fair value of $2.6 million is included in Property and equipment, net within the Consolidated Balance Sheet as of May 31, 2020. Liabilities of $0.3 million and $2.9 million related to these assets are included in Current portion of lease liabilities and Long-term lease liabilities, respectively, within the Consolidated Balance Sheet as of May 31, 2020. In the first quarter of fiscal year 2021, the Company sold its interest in Ontario. The Company received net cash proceeds of $4.9 million in connection with the sale and recorded a gain of $2.8 million during the nine months ended February 28, 2021, which is included in Restructuring costs within the Consolidated Statements of Comprehensive (Loss) Income.
On June 25, 2020 the Board of Directors approved a plan to close Curation Foods’ underutilized manufacturing operations in Hanover, Pennsylvania (“Hanover”), sell the building and assets related thereto, and consolidate its operations into its manufacturing facilities in Guadalupe, California and Bowling Green, Ohio. The $17.2 million carrying value of these assets is included in Property and equipment, net on the consolidated Balance Sheets as of May 31, 2020, and was not classified as assets held for sale as the plan to sell was not finalized until subsequent to fiscal year end 2020. In the first quarter of fiscal year 2021, the Company recognized an $8.8 million impairment loss, which is included in Restructuring costs within the Consolidated Statements of Comprehensive (Loss) Income. During the second quarter of fiscal year 2021, the Company sold the Hanover building and assets related thereto for net proceeds of $8.0 million.
Leases
Under Topic 842, the Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is a quoted rate based on the understanding of what the Company's credit rating would be. Certain agreements may contain the option to extend the lease term, terminate the lease before the contractual expiration date, or purchase the leased asset. The Company, when reasonably certain to exercise the option, considers these options in determining the measurement of the lease. The Company's lease agreements do not contain any material residual value guarantees.
The Company's lease agreements generally contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. The Company combines fixed payments for non-lease components with lease payments and accounts for them together as a single lease component which increases the amount of lease assets and liabilities.
Payments under lease arrangements are primarily fixed; however, certain lease agreements contain variable payments, which are expensed as incurred and are not included in the operating lease assets and liabilities. These amounts primarily include payments affected by changes in price indices.
Intangible Assets

The Company’sCompany’s intangible assets are comprised of customer relationships with a finite estimated useful life of elevenranging from 11 years to thirteen13 years, and trademarks, trademarks/tradenames and goodwill with indefinite useful lives.

Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be recoverable. Indefinite lived intangible assets are reviewed for impairment at least annually. For goodwill and other indefinite-lived intangible assets, the Company performs a qualitative impairment analysis in accordance with Accounting Standards Codification (“ASC”)ASC 350-30-35.

-7-

Table of Contents

Partial Self-Insurance on Employee Health and Workers Compensation Plans

The Company provides health insurance benefits to eligible employees under self-insured plans whereby the Company pays actual medical claims subject to certain stop loss limits and self-insures its workers compensation claims. The Company records self-insurance liabilities based on actual claims filed and an estimate of those claims incurred but not reported. Any projection of losses concerning the Company's liability is subject to a high degree of variability. Among the causes of this variability are unpredictable external factors such as inflation rates, changes in severity, benefit level changes, medical costs, and claims settlement patterns. This self-insurance liability is included in Other accrued liabilities in the accompanying Consolidated Balance Sheets and represents management's best estimate of the amounts that have not been paid as of November 26, 2017 and May 28, 2017. It is reasonably possible that the expense the Company ultimately incurs could differ and adjustments to future reserves may be necessary.

Fair Value Measurements

The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for its investmentinvestment in a non-public company. See Note 3 – Investment in Non-public Company for further information. The Company also measures its contingent consideration at fair value. See Note 2 – Acquisition of O Olive for further information. The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.

-10-

Table of Contents
The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – observable inputs such as quoted prices for identical instruments in active markets.

Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.

Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.

As of November 26, 2017February 28, 2021 and May 28, 2017,31, 2020, the Company held certain assets and liabilities that are required or it elected to be measured at fair value on a recurring basis, including its interest rate swap contracts and its minority interest investment in Windset.

The fair value of the Company’sCompany’s interest rate swap contracts is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level 2 fair value measurement investment and is included in Other assets or Other non-current liabilities in the accompanying Consolidated Balance Sheets.

As of February 28, 2021 and May 31, 2020, the Company held certain assets that were required to be measured at fair value on a non-recurring basis. The fair market value of the Company’s contingent considerationassets held for sale, less the acquisitioncosts to sell, was $0.0 million and $2.6 million as of O Olive utilizes significant unobservable inputs, including projected earnings before interest, taxes, depreciationFebruary 28, 2021 and amortization (“EBITDA”) and discount rates. As a result, the Company’s contingent consideration associated with the O Olive acquisition is considered a Level 3 measurement liability. For the three and six months ended November 26, 2017, the Company reduced its contingent consideration liability from $5.9 million at May 28, 2017 to $5.4 million at November 26, 2017 due to change in projected EBITDA and discount rates during the three year earn out period ended May 31, 2020.

2020, respectively. The fair market value of Ontario (classified as an asset held for sale) as of May 31, 2020, was based on third-party valuations, which primarily used the market approach, and the inputs utilized were comparable sales of similar assets, which are generally unobservable and are supported by little or no market data, and therefore were classified within Level 3.

The Company has elected the fair value option of accounting for its investment in Windset. The calculation of fair value utilizes significant unobservable inputs, including projected cash flows, growth rates,, and discount rates. As a result, the Company’s investment in Windset is considered to be a Level 3 measurement investment. The change in the fair value of the Company’s investment in Windset for the sixthree and nine months ended November 26, 2017February 28, 2021, was due to the Company’sCompany's 26.9% minority interest in the change in the fair market value of Windset during the period.
In determining the fair value of the investment in Windset, the Company utilizes the following significant unobservable inputs in the discounted cash flow models:

  

At November 26, 2017

  

At May 28, 2017

 

Revenue growth rates

  4%   4% 

Expense growth rates

  4%   4% 

Income tax rates

  15%   15% 

Discount rates

  12%   12% 

February 28, 2021 Range
(Weighted Average)
May 31, 2020 Range
(Weighted Average)
Revenue growth rates7% (6.9)%6% to 7% (6.4)%
Expense growth rates0% to 8% (5.5)%6% to 8% (6.6)%
Discount rates10%12%
-8-

Table of Contents

The revenue growth,and expense growth, and income tax rate assumptions are considered to be the Company's best estimate of the trends in those items over the discount period. The discount rate assumption takes into account the risk-free rate of return, the market equity risk premium, and the company’s specific risk premium and then applies an additional discount for lack of liquidity of the underlying securities. The discounted cash flow valuation model used by the Company has the following sensitivity to changes in inputs and assumptions (in thousands):

  

Impact on value of

investment in Windset

as of November 26, 2017

 

10% increase in revenue growth rates

 $7,400 

10% increase in expense growth rates

 $(2,000

)

10% increase in income tax rates

 $(500

)

10% increase in discount rates

 $(4,500

)

assumptions:

(In thousands)Impact on value of investment in Windset as of February 28, 2021
10% increase in revenue growth rates$6,000 
10% increase in expense growth rates$(3,200)
10% increase in discount rates$(1,300)

Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

-11-

Table of Contents
The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring basis (in thousands):

  

Fair Value at November 26, 2017

  

Fair Value at May 28, 2017

 

 

 

Level 1

  

Level 2

  

Level 3

  

Level 1

  

Level 2

  

Level 3

 
Assets:                        

Interest rate swap (1)

 $  $909  $  $  $688  $ 

Investment in non-public company

        65,800         63,600 

Total

 $  $909  $65,800  $  $688  $63,600 

and nonrecurring basis:

(In thousands)Fair Value at February 28, 2021Fair Value at May 31, 2020
Assets:Level 1Level 2Level 3Level 1Level 2Level 3
Assets held for sale - nonrecurring$$$$$$2,607 
Investment in non-public company45,100 56,900 
Total assets$$$45,100 $$$59,507 
Liabilities:
Interest rate swap contracts$$2,174 $$$3,578 $
Total liabilities$$2,174 $$$3,578 $

The following table reflects the fair value roll forward reconciliation of Level 3 assets and liabilities measured at fair value for the nine months ended February 28, 2021:

(1)

Included in Other assets.

(In thousands)Windset Investment
Balance as of May 31, 2020$56,900 
Fair value change(11,800)
Balance as of February 28, 2021$45,100 


Revenue Recognition

See Note 9 – Business Segment Reporting,

The Company follows the five step, principles-based model to recognize revenue upon the transfer of promised goods or services to customers and in an amount that reflects the consideration for a discussion aboutwhich the Company’s four business segments; namely, Packaged Fresh Vegetables, Food Export, Biomaterials,Company expects to be entitled in exchange for those goods or services. Revenue, net of estimated allowances and Other.

Revenue from product salesreturns, is recognized when thereor as the Company satisfies its performance obligations under a contract and control of the product is persuasive evidence that an arrangement exists, title has transferred to the price is fixed and determinable, and collectability is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns, and discounts based on specific identification and historical losses.

Apio’s Packaged Fresh Vegetables revenues generally consistcustomer.

Curation Foods
Curation Foods’ standard terms of revenues generated from the sale of specialty packaged fresh-cut and whole value-added vegetable products that are generally washedincluded in its contracts and packaged in Apio’s proprietary packaging and sold under Apio’s Eat Smart and GreenLine brands and various private labels.purchase orders. Revenue is generally recognized at the time shipment is made or upon shipmentdelivery as control of these productsthe product is transferred to customers. The Company takes titlethe customer. Shipping and other transportation costs charged to all produce it trades and/or packages, and therefore, records revenuescustomers are recorded in both revenue and cost of goods sold. Curation Foods’ has elected to account for shipping and handling as fulfillment activities, and not as a separate performance obligation. Curation Foods’ standard payment terms with its customers generally range from 30 days to 90 days. Certain customers may receive cash-based incentives (including: volume rebates, discounts, and promotions), which are accounted for as variable consideration to Curation Foods’ performance obligations. Curation Foods’ estimates these sales at gross amountsincentives based on the expected amount to be provided to its customers and reduces revenues recognized towards its performance obligations. The Company has not historically had and does not anticipate significant changes in its estimates for variable consideration.
Lifecore
Lifecore generates revenue from two integrated activities: Contract development and manufacturing organization ("CDMO") and Fermentation. CDMO is comprised of aseptic and development services. Lifecore’s standard terms of sale are generally included in its contracts and purchase orders. Shipping and other transportation costs charged to customers are recorded in both revenue and cost of goods sold. Lifecore has elected to account for shipping and handling as fulfillment activities, and not as a separate performance obligation. Lifecore’s standard payment terms with its customers generally range from 30 days to 60 days.
Aseptic
Lifecore provides aseptic formulation and filling of syringes and vials with precisely formulated medical grade HA and non-HA materials for injectable products used for medical purposes. In instances where our customers contract with us to aseptically fill syringes or vials with our HA, the goods are not distinct in the accompanying Consolidated Statements of Comprehensive Income.

In addition, Packaged Fresh Vegetables revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position, and from the sale of BreatheWay® packaging to license partners. Revenue is recognized on the vegetable cooling operations as cooling and storage services are provided to Apio’s customers. Sales of BreatheWay packaging are recognized when shipped to Apio’s customers.

Apio’s Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia through its subsidiary, Cal-Ex Trading Company (“Cal-Ex”). As most Cal-Ex customers are in countries outsidecontext of the U.S., title transfers andcontract. Lifecore recognizes revenue is generally recognized upon arrival offor these products at the shipmentpoint in the foreign port. Apio records revenue equal to the sale price to third parties because it takestime when legal title to the product while in transit.

Lifecore’s Biomaterials business principally generates revenue throughis transferred to the salecustomer, which is at the time that shipment is made or upon delivery of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 65% of Lifecore’s revenues in fiscal year 2017, (2) Orthopedic, which represented approximately 15% of Lifecore’s revenues in fiscal year 2017, and (3) Other/Non-HA products, which represented approximately 20% of Lifecore’s revenues in fiscal year 2017. The vast majority of Lifecore’s revenues are recognized upon shipment.

Lifecore’s business development revenues, a portion of which are included in all three medical areas, are related to contract research and development (“R&D”) services and multiple element arrangement services with customers where the Company provides products and/or services in a bundled arrangement.

product.
-9-
-12-

Table of Contents

O Olive’s business, which

Development Services
Lifecore provides product development services to assist its customers in obtaining regulatory approval for the commercial sale of their drug product. These services include activities such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation and production of materials for use within clinical studies. The Company’s customers benefit from the expertise of its scientists who have extensive experience performing such tasks.
Each of the promised goods and services are not distinct in the context of the contract as the goods and services are highly interdependent and interrelated. The services described above are significantly affected by each other because Lifecore would not be able to fulfill its promise by transferring each of the goods or services independently.
Revenues generated from development services arrangements are recognized over time as Lifecore is creating an asset without an alternate use as it is unique to the customer. Furthermore, the Company acquiredhas an enforceable right to payment for the performance completed to date for its costs incurred in satisfying the performance obligation plus a reasonable profit margin. For each of the development activities performed by Lifecore as described above, labor is the primary input (i.e., labor costs represent the majority of the costs incurred in the completion of the services). The Company determined that labor hours are the best measure of progress as it most accurately depicts the effort extended to satisfy the performance obligation over time.
Fermentation
Lifecore manufactures and sells pharmaceutical-grade sodium hyaluronate (“HA”) in bulk form to its customers. The HA produced is distinct as customers are able to utilize the product provided under HA supply contracts when they obtain control. Lifecore recognizes revenue for these products at the point in time when legal title to the product is transferred to the customer, which is at the time that shipment is made or upon delivery of the product to our customer.
The Company disaggregates its revenue by segment based on March 1, 2017, sells premier California specialty olive oilshow it markets its products and wine vinegarsservices and reviews results of operations. The following tables disaggregate segment revenue by major product lines and services (in thousands):

(In thousands)Three Months EndedNine Months Ended
Curation Foods:February 28, 2021February 23, 2020February 28, 2021February 23, 2020
Fresh packaged salads and vegetables$94,739 $110,884 $283,341 $325,628 
Avocado products15,378 14,517 47,107 44,738 
Technology440 2,081 1,632 3,540 
Total$110,557 $127,482 $332,080 $373,906 

(In thousands)Three Months EndedNine Months Ended
Lifecore:February 28, 2021February 23, 2020February 28, 2021February 23, 2020
Contact development and manufacturing organization$18,628 $14,004 $53,374 $43,118 
Fermentation8,597 11,442 18,874 17,211 
Total$27,225 $25,446 $72,248 $60,329 

Contract Assets and Liabilities
Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. The Company’s contract assets as of February 28, 2021 and May 31, 2020, were $10.6 million and $9.0 million, respectively.
Contract liabilities primarily relate to payments received from customers in advance of performance under the O brand to natural food, conventional grocerycontract. The Company’s contract liabilities as of February 28, 2021 and mass retail stores, primarily inMay 31, 2020, were $1.1 million and $0.0 million, respectively. Revenue recognized during the United Statesthree and Canada. The revenues of O Olive arenine months ended February 28, 2021, that was included in the Other segment. O Olive’s revenue is generally recognized upon shipmentcontract liability balance at the beginning of its productsfiscal year 2021, was $0.0 million.
-13-

Table of Contents
Shipping and Handling Costs
Amounts billed to customers. The Company takes title to all products it trades and/or packages,third-party customers for shipping and therefore, records revenueshandling are included as a component of revenues. Shipping and handling costs incurred are included as a component of cost of sales at gross amounts inproducts sold and represent costs incurred to ship product from the accompanying Consolidated Statements of Comprehensive Income.

Contract R&D revenue is recorded as earned, based on the performance requirements of the contract. Non-refundable contract fees for which no further performance obligations exist, and there is no continuing involvement by the Company, are recognized on the earlier of when the payment is receivedprocessing facility or collectability is reasonably assured.

For sales arrangements that contain multiple elements, the Company splits the arrangement into separate units of accounting if the individually delivered elements have valuedistribution center to the customer on a standalone basis. The Company also evaluates whether multiple transactions with the same customer or related party should be considered part of a multiple element arrangement, whereby the Company assesses, among other factors, whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of each other. The Company then allocates revenue to each element based on a selling price hierarchy. The relative selling price for a deliverable is based on its vendor-specific objective evidence (“VSOE”), if available, third-party evidence (“TPE”), if VSOE is not available, or estimated selling price, if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its policies for product and service revenue recognition. The Company is not typically able to determine VSOE or TPE, and; therefore, uses the estimated selling price to allocate revenue between the elements of an arrangement.

The Company limits the amount of revenue recognition for delivered elements to the amount that is not contingent on the future delivery of products or services or future performance obligations or subject to customer-specific cancellation rights. The Company evaluates each deliverable in an arrangement to determine whether it represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value, and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by the Company. The Company considers a deliverable to have stand-alone value if the product or service is sold separately by the Company or another vendor or could be resold by the customer. Further, the revenue arrangements generally do not include a general right of return relative to delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition. The Company allocates the total arrangement consideration to each separable element of an arrangement based upon the relative selling price of each element. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where the Company has not established fair value for any undelivered element, revenue for all elements is deferred until delivery of the final element is completed and all recognition criteria are met.

For licensing revenue, the initial license fees are deferred and amortized to revenue over the period of the agreement when a contract exists, the fee is fixed and determinable, and collectability is reasonably assured. Noncancellable, nonrefundable license fees are recognized over the period of the agreement, including those governing R&D activities and any related supply agreement entered into concurrently with the license when the risk associated with commercialization of a product is non-substantive at the outset of the arrangement.

From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are estimated on a quarterly basis and recorded as a reduction of revenue.

A summary of revenues by type of arrangement as described above is as follows (in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

November 26, 2017

  

November 27, 2016

 

Recorded upon shipment

 $118,634  $107,987  $231,908  $214,152 

Recorded upon acceptance in foreign port

  13,996   25,701   21,572   49,040 

Revenue from multiple element arrangements

  2,132   1,683   3,701   3,268 

Revenue from license fees, R&D contracts and royalties/profit sharing

  1,695   494   2,633   1,799 

Total

 $136,457  $135,865  $259,814  $268,259 

end consumer markets.


Legal Contingencies

In the ordinary course of business, the Company is involved in various legal proceedings and claims.

The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adjustedadjusted to reflect the impacts of negotiations, estimateestimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.

Claims Alleging Unfair Labor Practices
-10-

Table of Contents

ApioCuration Foods has been the target of a union organizing campaign which has included two3 unsuccessful attempts to unionize Apio'sCuration Foods’ Guadalupe, California processing plant. The campaign has involved a union and over 100 former and current employees of Pacific Harvest, Inc. and Rancho Harvest, Inc. (collectively "Pacific Harvest"), Apio'sCuration Foods’ former labor contractors at its Guadalupe, California processing facility, bringing legal actions before various state and federal agencies, the California Superior Court, and initiating over 100 individual arbitrations against ApioCuration Foods and Pacific Harvest.

The legal actions consistconsisted of three main typesvarious claims, all of claims: (1) Unfair Labor Practice claims ("ULPs") before the National Labor Relations Board (“NLRB”), (2) discrimination/wrongful termination claims before state and federal agencies andwhich were settled in individual arbitrations, and (3) wage and hour claims asfiscal year 2017. As part of two Private Attorney General Act (“PAGA”) cases in state court and in over 100 individual arbitrations.

Athe settlement agreement, Pacific Harvest agreed to pay the Company one half of the ULPs amongrequired settlement payments. As of May 31, 2020, the union, Apio, and Pacific Harvest that were pending beforeoutstanding balance of the NLRBreceivable was approved on December 27, 2016 for $310,000. Apio was responsible for half of this settlement, or $155,000. On May 5, 2017, the parties$1.2 million. The Company makes ongoing estimates relating to the remaining actions executedcollectability of receivables. A reserve is established for any note when there is reasonable doubt that the principal or interest will be collected in full. The Company may write-off uncollectable receivables after collection efforts are exhausted. During the fiscal year 2020, the Company’s review for collectability concluded that a settlement agreement concerning the discrimination/wrongful termination claims and the wage and hour claims which covers all non-exempt employeesreceivable reserve of $1.2 million would be recorded. The Company's conclusion regarding collectability changed as a result of Pacific Harvest workingcommunicating their refusal to pay combined with their bringing claims against the Company. As of February 28, 2021, the reserve balance remained at $1.2 million.

Compliance Matters and Related Litigation
On December 1, 2018, the Company acquired all of the voting interests and substantially all of the assets of Yucatan Foods (the “Yucatan Acquisition”), which owns a guacamole manufacturing plant in Mexico called Procesadora Tanok, S de RL de C.V. (“Tanok”).
On October 21, 2019, the Company retained Latham & Watkins, LLP to conduct an internal investigation relating to potential environmental and Foreign Corrupt Practices Act (“FCPA”) compliance matters associated with regulatory permitting at Apio's Guadalupe,the Tanok facility in Mexico. The Company subsequently disclosed to the SEC and the U.S. Department of Justice (“DOJ”) the conduct under investigation, and these agencies have commenced an investigation. The Company has also disclosed the conduct under investigation to the Mexican Attorney General’s Office, which has commenced an investigation, and to Mexican regulatory agencies. The Company is cooperating in the government investigations and requests for information. The conduct at issue began prior to the Yucatan Acquisition, and the agreement for the Yucatan Acquisition provides the Company with certain indemnification rights that may allow the Company to recover the cost of a portion of the liabilities that have been and may be incurred by the Company in connection with these compliance matters. On September 2, 2020, one of the former owners of Yucatan filed a lawsuit against the Company in Los Angeles County Superior Court for breach of employment agreement, breach of contract, breach of holdback agreement, declaratory relief and accounting, and related claims. The Plaintiff seeks over $10 million in damages, including delivery of shares of his stock held in escrow for the indemnification claims described above. On November 3, 2020, the Company filed an answer and cross-complaint against the Plaintiff and other parties for fraud, indemnification, and other claims, and seeking no less than $80 million in damages.
At this stage, the ultimate outcome of these or any other investigations, legal actions, or potential claims that may arise from the matters under investigation is uncertain and the Company cannot reasonably predict the timing or outcomes, or estimate the amount of net loss after indemnification, or its effect, if any, on its financial statements. Separately, there are indemnification provisions in the purchase agreement that may allow the Company to recover costs for fraud or breach of the purchase agreement from the seller.
-14-

Table of Contents
During the third quarter of fiscal year 2021 the Company reached a resolution with its insurance carrier that resulted in a recovery of approximately $1.6 million which is recorded as a reduction of selling, general and administrative in the Consolidated Statements of Comprehensive (Loss) Income for the three and nine months ended February 28, 2021. Absent further material developments in the investigation, the Company does not expect additional material recovery from the insurance carrier.
Other Litigation Matters
On February 10, 2020, a complaint was filed against Curation Foods in the United States District Court for the Northern District of Georgia, Printpack, Inc. v. Curation Foods, Inc., alleging breach of contract pertaining to Curation Foods’ purchase of certain poly film packaging from the plaintiff. The plaintiff sought an unspecified amount of monetary damages, litigation expenses, and interest. The lawsuit was dismissed during the first quarter of fiscal year 2021.
On February 14, 2020, a complaint was filed against the Company, Curation Foods, the Company's current CEO Albert Bolles, and the Company’s former CFO Gregory Skinner (collectively, the “Landec Parties”), and other defendants in Santa Barbara County Superior Court, entitled Pacific Harvest, Inc., et al. v. Curation Foods, Inc., et al. (No. 20CV00920). The case was brought by Pacific Harvest, Inc. (“Pacific”) and Rancho Harvest, Inc. (“Rancho”), two related companies that have provided labor and employee staffing services to Curation Foods. Among other things, Pacific and Rancho allege that Curation Foods wrongfully decreased its use of Pacific’s staffing services and misappropriated Pacific’s trade secrets when Curation Foods increased its use of another staffing company and transitioned Pacific’s employees to the other staffing company. Pacific and Rancho also allege that Curation Foods breached agreements between the parties related to a loan from Curation Foods, on which Pacific and Rancho have ceased making payments. Pacific Harvest and Rancho assert claims for breach of contract, breach of the implied covenant of good faith and fair dealing, intentional interference with contracts and potential economic advantage, misappropriation of trade secrets under California’s Uniform Trade Secrets Act, business practices in violation of California processing facility from September 2011 throughUnfair Competition Law, fraud, defamation, violation of California Usury Law, breach of fiduciary duty, and declaratory relief regarding the parties’ rights and obligations under certain of the parties’ contracts. The Landec Parties have not yet responded to the complaint, and the parties have filed stipulations to continue the time for allowing Pacific and Rancho to file an amended complaint. Subsequent to the third quarter of fiscal year 2021, on March 15, 2021, the Company executed a settlement date. Underagreement related to this matter. The loss contingency of approximately $1.8 million that was realized is after considering the total settlement amount and insurance recoveries, and this amount is included in Legal settlement charge in the Consolidated Statements of Comprehensive (Loss) Income for the nine months ended February 28, 2021, and is consistent with the estimated amounts recorded during the second quarter of fiscal 2021. The Company expects that the final settlement amount will be paid to the plaintiffs by Curation Foods (and separately by its co-defendants and insurers) by April 14, 2021. Pursuant to the settlement agreement, the plaintiffs are expected to request that the case be paid $6.0 million in three installments: $2.4 million, which was paid on July 3, 2017, $1.8 million which was paid on November 22, 2017 and $1.8 million which is due in July 2018. The Company and Pacific Harvest have each agreed to pay one halfdismissed within five days of receiving the settlement payments. The Company paid the entire first two installments of $4.2 million and will be reimbursed by Pacific Harvest for its $2.1 million portion which is included in Other assets in the accompanying Consolidated Balance Sheets. This receivable will be repaid through monthly payments until fully paid, which the Company expects to occur by December 2020. The Company and Pacific Harvest will both make one half of the third installment in July 2018. The Company’s recourse against non-payment by Pacific Harvest is its security interest in assets owned by Pacific Harvest.

As of November 26, 2017 and May 28, 2017, the Company had accrued $1.0 million and $3.2 million, respectively, related to these actions, which is included in Other accrued liabilities in the accompanying Consolidated Balance Sheets.

payment.


Recent Accounting Guidance Not Yet
Recently Adopted

Revenue Recognition

Pronouncements

Cloud Computing Arrangements
In May 2014,August 2018, the FASB issued ASU 2014-09,2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract (“ASU 2018-15”), which createsrequires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to defer and recognize as an asset. The Accounting Standards Update generally aligns the guidance on recognizing implementation costs incurred in a cloud computing arrangement that is a service contract with that for implementation costs incurred to develop or obtain internal-use software, including hosting arrangements that include an internal-use software license. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application is permitted. The Company adopted ASU 2018-15 on June 1, 2020, and the adoption of this standard did not have an impact on the Company’s consolidated financial statements.
Fair Value Measurement
In August 2018, the FASB ASC Topic 606, Revenue from Contracts with Customers and supersedes ASC Topic 605, Revenue Recognitionissued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2014-09”2018-13”). The guidance replaces industry-specific guidanceeliminates, adds, and establishes a single five-step modelmodifies certain disclosure requirements for fair value measurements. Entities will no longer have to identifydisclose the amount of and recognize revenue. The core principlereasons for transfers between Level 1 and Level 2 of the guidance is that an entity should recognize revenue upon transfer of control of promised goods or services to customers in an amount that reflects the consideration to which an entity expects tofair value hierarchy, but will be entitled in exchange for those goods or services. Additionally, the guidance requires the entityrequired to disclose further quantitativethe range and qualitative information regarding the natureweighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and amount of revenues arising from contracts with customers, as well as other information about the significant judgments and estimates used in recognizing revenues from contracts with customers. Since its original issuance, the FASB has issued several additional related ASUs to address implementation concerns and to further clarify certain guidanceinterim periods within ASU 2014-09.those fiscal years, beginning after December 15, 2019. The Company will adopt these updates beginning with the first quarter of its fiscal year 2019adopted ASU 2018-13 on June 1, 2020, and anticipates doing so using the full retrospective method, which will require restatement of each prior reporting period presented.

Currently, the Company is in the process of evaluating the impact of the adoption of this standard did not have an impact on the Company’s consolidated financial statements. As required by ASU 2014-09. As a result,2018-13, the Company has initially identified the following core revenue streams from its contracts with customers:

Finished goods product sales (Packaged Fresh Vegetables and O Olive);

Shipping and handling (Packaged Fresh Vegetables and O Olive);

Buy-sell product sales (Food Export);

Product development and contract manufacturing arrangements (Biomaterials).

The Company’s assessment efforts to date have included reviewing current accounting policies, processes, and systems requirements, as well assigning internal resources and third-party consultants to assist in the process. Additionally, the Company has begun to review historical contracts and other arrangements to identify potential differences that could arise from the adoption of ASU 2014-09. Most notably, the Company is evaluating its current conclusions with respect to gross versus net revenue reporting for its Food Export business, as well as the timing of revenue recognition for its product development contract manufacturing arrangements in its Biomaterials business, to determine whether the application of ASU 2014-09 necessitates changes to such reporting. Beyond its core revenue streams, and the items listed above, the Company is also evaluating the impact of ASU 2014-09 on certain ancillary transactions and other arrangements.

-11-
-15-

Table of Contents

Currently,

additional disclosures in the Company cannot reasonably estimateFair Value Measurement section related to the impactrange and weighted average rates used to develop significant inputs for the application of ASU 2014-09 will have upon its consolidated financial statements. The Company continues to assess the impact of ASU 2014-09, along with industry trends and additional interpretive guidance, on its core revenue streams, and as a result of the continued assessment, the Company may modify its plan of adoption accordingly.

Leases

Level 3 investment.

Financial Instruments – Credit Losses
In FebruaryJune 2016, the FASB issuedissued ASU 2016-02, LeasesNo. 2016-13, Financial Instruments —Credit Losses (Topic 842) (“326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-02”2016-13”), which requires companies to generally recognizemeasurement and recognition of expected credit losses for financial assets held. Effective June 1, 2020, the Company adopted ASC 326 using the transition method introduced by ASU 2016-13. The adoption of ASC 326 did not have a material impact on the balance sheet operating and financing lease liabilities and corresponding right-of-use-assets. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The Company will adopt ASU 2016-02 beginning in the first quarter of fiscal year 2020 on a modified retrospective basis.

The Company is currently in the process of evaluating the impact that ASU 2016-02 will have upon itsour consolidated financial statements and related disclosures. The Company’sstatements.

Under ASC 326, the Company changed its policy for assessing credit losses to include consideration of a broader range of information to estimate credit losses over the life of its financial assets. As of February 28, 2021 the financial assets of the Company within the scope of the assessment efforts to date have included:

Reviewing the provisions of ASU 2016-02;

Gathering information to evaluate its lease population and portfolio;

Evaluating the nature of its real and personal property and other arrangements that may meet the definition of a lease; and

Evaluating systems’ readiness.

As a resultcomprised of these efforts, the Company currently anticipates that the adoption of ASU 2016-02 will have a significant impact to its long-termtrade accounts receivable, contract assets, and liabilities, as, at a minimum, virtually all of its leases designated as operating leases are expected to be reported on deposits. Seethe consolidated balance sheets. The pattern of recognitionAccounts Receivable and Sales Returns and Allowance for operating leasesCredit Losses section within the consolidated statements of comprehensive income is not anticipated to significantly change.

2.

Acquisition of O Olive

On MarchNote 1 2017, the Company purchased substantially allfor further discussion of the assets of O OliveCompany's accounting for $2.5 millioncredit losses.


2.    Investment in cash plus contingent consideration of up to $7.5 million over the next three years based upon O Olive achieving certain EBITDA targets. All accounting for this acquisition is final.

The potential earn out payment up to $7.5 million is based on O Olive’s cumulative EBITDA over the Company’s fiscal years 2018 through 2020. At the end of each fiscal year, beginning in fiscal year 2018, the former owners of O Olive will earn the equivalent of the EBITDA achieved by O Olive for that fiscal year up to $4.6 million over the three year period. The former owners can also earn an additional $2.9 million on a dollar for dollar basis for exceeding $6.0 million of cumulative EBITDA over the three year period.  During the second quarter of fiscal year 2018, theNon-public Company performed, with the assistance of a third party appraiser, an analysis of O Olive’s projected EBITDA over the earnout period. Based on this analysis the Company has recorded a contingent consideration liability, included in Other non-current liabilities, of $5.4 million and $5.9 million as of November 26, 2017 and May 28, 2017, respectively, representing the present value of the expected earn out payments. The $500,000 reduction in the contingent consideration liability was recorded as a reduction to SG&A in the accompanying Consolidated Statements of Comprehensive Income. For this analysis, the Company assumed that the maximum earn out of $7.5 million would be paid over the three year period with over half being earned in fiscal year 2020.  

The operating results of O Olive are included in the Company’s financial statements beginning March 1, 2017, in the Other segment.

Intangible Assets

The Company identified two intangible assets in connection with the O Olive acquisition: trade names and trademarks valued at $1.6 million, which are considered to be indefinite lived intangible assets and therefore, will not be amortized; and customer relationships valued at $700,000 with an eleven year useful life. The Company recorded $16,000 and $48,000 of amortization expense from the amortization of the customer relationships intangible during the three and six months ended November 26, 2017, respectively. The trade name/trademark intangible asset was valued using the relief from royalty valuation method and the customer relationship intangible asset was valued using the excess earnings method.

-12-

Table of Contents

3.

Investment in Non-public Company

On February 15, 2011, Apio Curation Foods entered into a share purchase agreement (the “Windset Purchase Agreement”) with Windset. Pursuant to the Windset Purchase Agreement, ApioCuration Foods purchased from Windset 150,000 Senior A preferred shares for $15$15.0 million and 201 common shares for $201. On July 15, 2014, ApioCuration Foods increased its investment in Windset by purchasing from the Newell Capital Corporation an additional 68 common shares and 51,211 junior preferred shares of Windset for $11$11.0 million. After this purchase, the Company’s common shares represent a 26.9% ownership interest in Windset. The Senior A preferred shares yield a cash dividend of 7.5% annually. The dividend is payable within 90 days of each anniversary of the execution of the Windset Purchase Agreement. The non-voting junior preferred stock does not yield a dividend unless declared by the Board of Directors of Windset and no0 such dividend has been declared.

The Shareholders’ Agreement between ApioCuration Foods and Windset, as amended on March 15, 2017, includes a put and call option (the “Put and Call Option”), which can be exercised on or after March 31, 2022, whereby ApioCuration Foods can exercise the put to sell its common, Senior A preferred shares, and junior preferred shares to Windset, or Windset can exercise the call to purchase those shares from Apio,Curation Foods, in either case, at a price equal to 26.9% of the fair market value of Windset’s common shares, plus the liquidation value of the preferred shares of $20.1 million ($1515.0 million for the Senior A preferred shares and $5.1 million for the junior preferred shares). Under the terms of the arrangement with Windset, the Company is entitled to designate one of five members on the Board of Directors of Windset.

On October 29, 2014, Apio further increased its investment in Windset by purchasing 70,000 shares of Senior B preferred shares for $7 million.

The Senior B preferred shares pay an annual dividend of 7.5% on the amount outstanding at each anniversary date of the Windset Purchase Agreement. The Senior B preferred shares purchased by Apio have a put feature whereby Apio can sell back to Windset $1.5 million of shares on the first anniversary, an additional $2.75 million of shares on the second anniversary, and the remaining $2.75 million on the third anniversary. After the third anniversary, Apio may at any time put any or all of the shares not previously sold back to Windset. At any time on or after February 15, 2017, Windset has the right to call any or all of the outstanding common shares, but at such time must also call the same proportion of Senior A preferred shares, Senior B preferred shares, and junior preferred shares owned by Apio. Windset’s partial call provision is restricted such that a partial call cannot result in Apio holding less than 10% of Windset’s common shares outstanding.

The investment in Windset does not qualify for equity method accounting as the investment does not meet the criteria of in-substance common stock due to returns through the annual dividend on the non-voting senior preferred shares that are not available to the common stock holders.stockholders. As the put and call options require all of the various shares to be put or called in equal proportions, the Company has deemed that the investment, in substance, should be treated as a single security for purposes of accounting.

The fair value of the Company’sCompany’s investment in Windset was determined utilizing the Windset Purchase Agreement’s put/put and call calculation for value and a discounted cash flow model based on projections developed by Windset that were reviewed by Landec, and considers the put and call conversion options. These features impact the duration of the cash flows utilized to derive the estimated fair values of the investment. These two discounted cash flow models’ estimate for fair value are then weighted. Assumptions included in these discounted cash flow models will be evaluated quarterly based on Windset’s actual and projected operating results to determine the change in fair value.


Duringeach of the three month periodsmonths ended November 26, 2017February 28, 2021 and November 27, 2016,February 23, 2020, the Company recorded $412,000$0.3 million and $0.3 million, respectively, in dividend income. During each of the six month periodsnine months ended November 26, 2017February 28, 2021 and November 27, 2016,February 23, 2020, the Company recorded $825,000$0.8 million and $0.8 million, respectively, in dividend incomeincome. The increasechange in the fair market value of the Company’s investment in Windset for the six month periodsthree months ended November 26, 2017February 28, 2021 and November 27, 2016February 23, 2020, was $2.2$0.0 million and $0,$0.0 million, respectively. The change in the fair market value of the Company’s investment in Windset for the nine months ended February 28, 2021 and February 23, 2020, was a decrease of $11.8 million and an increase of $0.2 million, respectively, and is included in Other income (expense) in the accompanying Consolidated Statements of Comprehensive (Loss) Income.

4.

Stock-Based Compensation

The change in the fair market value of the Company's investment in Windset for the nine months ended February 28, 2021 was primarily due to changes in the financial assumptions relating to EBITDA, non-productive assets, and debt levels.



-16-

Table of Contents
3.    Stock-based Compensation and Stockholders' Equity
Stock-Based Compensation Activity
The estimated fair value for stock options, which determines the Company’s calculation of stock-based compensation expense, is based on the Black-Scholes option pricing model. Restricted stock units (“RSUs”) are valued at the closing market price of the Company’s common stock on the grant date. The Company’s uses the straight-line method to recognize the fair value of stock-based compensation arrangements.
During the three months ended February 28, 2021, the Company granted 100,000 options to purchase shares of common stock and awarded 17,500 RSUs. During the nine months ended February 28, 2021, the Company granted 672,600 options to purchase shares of common stock and awarded 188,225 RSUs.
As of February 28, 2021, the Company has reserved 4.1 million shares of common stock for future issuance under its current and former equity plans.
Stock-Based Compensation Expense
The Company’s stock-based awards include stock option grants and RSUs. The Company records compensation expense for stock-based awards issued to employees and directors in exchange for services provided based on the estimated fair value of the awards on their grant datesdate and is recognized over the required service periods,period, generally the vesting period.

-13-

Table of Contents

The following table summarizes the stock-based compensation for options and RSUs (in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

November 26, 2017

  

November 27, 2016

 

Options

 $354  $307  $678  $599 

RSUs

  762   659   1,388   1,174 

Total stock-based compensation

 $1,116  $966  $2,066  $1,773 

The following table summarizes the stock-based compensation by income statement line item (in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

November 26, 2017

  

November 27, 2016

 

Cost of sales

 $137  $124  $261  $237 

Research and development

  23   23   42   46 

Selling, general and administrative

  956   819   1,763   1,490 

Total stock-based compensation

 $1,116  $966  $2,066  $1,773 

The estimated fair value for stock options, which determines the Company’s calculation of stock-based compensation expense, is based on the Black-Scholes option pricing model. RSUs are valued at the closing market price of the Company’s common stock on the date of grant. The Company uses the straight-line method to recognize the fair value of stock-based compensation arrangements.

item:


Three Months EndedNine Months Ended
(In thousands)February 28, 2021February 23, 2020February 28, 2021February 23, 2020
Cost of sales$107 $(14)$289 $42 
Research and development49 10 175 88 
Selling, general and administrative641 570 2,120 1,751 
Total stock-based compensation$797 $566 $2,584 $1,881 

As of November 26, 2017,February 28, 2021, there was $6.2$4.1 million of total unrecognized compensation expense related to unvested equity compensation awards granted under the Landec incentive stock plans. Total expense is expected to be recognized over the weighted-average period of 2.52.24 years for stock options and 2.01.56 years for restricted stock unit awards.

5.

Diluted Net Income Per Share

The following table sets forth the computation of diluted net income per share (in thousands, except per share amounts):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

November 26, 2017

  

November 27, 2016

 

Numerator:

                

Net income applicable to Common Stockholders

 $487  $1,326  $2,633  $4,638 
                 

Denominator:

                

Weighted average shares for basic net income per share

  27,518   27,249   27,512   27,234 

Effect of dilutive securities:

                

Stock options and restricted stock units

  357   369   354   338 

Weighted average shares for diluted net income per share

  27,875   27,618   27,866   27,572 
                 

Diluted net income per share

 $0.02  $0.05  $0.09  $0.17 

For the three and six months ended November 26, 2017 the computation of the diluted net income per share excludes the impact of options to purchase 1.5 million and 1.4 million shares, respectively of Common RSUs.

Stock as such impacts would be antidilutive for this period.

6.

Income Taxes

The provision for income taxes for the six months ended November 26, 2017 was $1.5 million. The effective tax rate for the six months ended November 26, 2017 and November 27, 2016 was 36% and 34%, respectively. The effective tax rate for the six months ended November 26, 2017 was higher than the statutory federal income tax rate of 35% primarily due to state income taxes and incentive stock option expense; partially offset by the domestic manufacturing deduction and research and development credits. There are no significant discrete tax benefits included in the effective tax rate for the six months ended November 26, 2017.

Repurchase Plan
-14-

Table of Contents

As of November 26, 2017 and May 28, 2017, the Company had unrecognized tax benefits of approximately $535,000 and $537,000, respectively. Included in the balance of unrecognized tax benefits as of November 26, 2017 and May 28, 2017 is approximately $433,000 and $419,000, respectively, of tax benefits that, if recognized, would result in an adjustment to the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly within the next twelve months.

The Company has elected to classify interest and penalties related to uncertain tax positions as a component of its provision for income taxes. The Company has accrued an insignificant amount of interest and penalties relating to the income tax on the unrecognized tax benefits as of November 26, 2017 and May 28, 2017.

Due to tax attribute carryforwards, the Company is subject to examination for tax years 2013 forward for U.S. tax purposes. The Company is also subject to examination in various state jurisdictions for tax years 2012 forward, none of which were individually material.

Our estimated annual effective tax rate may be subject to further uncertainty due to the recent changes in U.S. tax rates and tax laws.

7.

Debt

Long-term debt, net consists of the following (in thousands):

  

November 26, 2017

  

May 28, 2017

 

Term loan with JPMorgan Chase Bank (“JPMorgan”), BMO Harris Bank N,A. (“BMO”), and City National Bank; due in quarterly principal and interest payments of $1,250 beginning December 1, 2016 through September 23, 2021 with the remainder due on maturity, with interest based on the Company’s leverage ratio at a per annum rate of the Eurodollar rate plus a spread of between 1.25% and 2.25%

 $45,000  $47,500 

Total principal amount of long-term debt

  45,000   47,500 

Less: unamortized debt issuance costs

  (231

)

  (261

)

Total long-term debt, net of unamortized debt issuance costs

  44,769   47,239 

Less: current portion of long-term debt, net

  (4,940

)

  (4,940

)

Long-term debt, net

 $39,829  $42,299 

On September 23, 2016, the Company entered into a Credit Agreement with JPMorgan, BMO, and City National Bank, as lenders (collectively, the “Lenders”), and JPMorgan as administrative agent, pursuant to which the Lenders provided the Company with a $100 million revolving line of credit (the “Revolver”) and a $50 million term loan facility (the “Term Loan”), guaranteed by each of the Company’s direct and indirect subsidiaries and secured by substantially all of the Company’s assets, with the exception of the Company’s investment in Windset.

Both the Revolver and the Term Loan mature in five years (on September 23, 2021), with the Term Loan providing for quarterly principal payments of $1.25 million commencing December 1, 2016, with the remainder due at maturity.

Interest on both the Revolver and the Term Loan is based on either the prime rate or Eurodollar rate, at the Company’s discretion, plus a spread based on the Company’s leverage ratio (generally defined as the ratio of the Company’s total indebtedness on such date to the Company’s consolidated EBITDA for the period of four consecutive fiscal quarters ended on or most recently prior to such date). The spread is at a per annum rate of (i) between 0.25% and 1.25% if the prime rate is elected or (ii) between 1.25% and 2.25% if the Eurodollar rate is elected.

The Credit Agreement provides the Company the right to increase the Revolver commitments and/or the Term Loan commitments by obtaining additional commitments either from one or more of the Lenders or another lending institution at an amount of up to $75 million.

The Credit Agreement contains customary financial covenants and events of default under which the obligation could be accelerated and/or the interest rate increased. The Company was in compliance with all financial covenants as of November 26, 2017.

On November 1, 2016, the Company entered into an interest rate swap agreement (“Swap”) with BMO at a notional amount of $50 million. The Swap has the effect of changing the Company’s Term Loan obligation from a variable interest rate to a fixed 30-day LIBOR rate of 1.22%. As of November 26, 2017, the interest rate on the Term Loan was 3.00%. For further discussion regarding the Company’s use of derivative instruments, see the Financial Instruments section of Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies.

-15-

Table of Contents

In connection with the Credit Agreement, the Company incurred lender and third-party debt issuance costs of $897,000, of which $598,000 and $299,000 was allocated to the Revolver and Term Loan, respectively.

As of November 26, 2017, $10 million was outstanding on the Revolver. As of November 26, 2017, the interest rate on the Revolver was 3.00% for the $6 million under the Libor option, and 4.25% for the $4 million under the Alternative Base Rate (Prime) option.

8.

Stockholders’ Equity

During the three months ended November 26, 2017, the Company granted options to purchase 393,000 shares of common stock and awarded 131,000 RSUs. During the six months ended November 26, 2017, the Company granted options to purchase 498,000 shares of common stock and awarded 200,000 RSUs.

As of November 26, 2017, the Company has reserved 3.2 million shares of Common Stock for future issuance under its current and former equity plans.

On July 14, 2010, the Company announced that the Board of Directors of the Company had approved the establishment of a stock repurchase plan, authorizingwhich allows for the repurchase of up to $10$10.0 million of the Company’sCompany’s common stock. The Company may still repurchase up to $3.8 million of the Company’s common stock under the Company’s stock repurchase plan. The Company may repurchase its common stock from time to time in open market purchases or in privately negotiated transactions. The timing and actual number of shares repurchased is at the discretion of management of the Company and will depend on a variety of factors, including stock price, corporate and regulatory requirements, market conditions, the relative attractiveness of other capital deployment opportunities and other corporate priorities. The stock repurchase program does not obligate Landec to acquire any amount of its common stock and the program may be modified, suspended or terminated at any time at the Company's discretion without prior notice. During the fiscal year ended May 28, 2017 and the sixnine months ended November 26, 2017,February 28, 2021, the Company did not0t purchase any shares on the open market.

9.

Business Segment Reporting


-17-

Table of Contents
4.    Diluted Earnings Per Share 
The following table sets forth the computation of diluted earnings per share:

Three Months EndedNine Months Ended
(In thousands, except per share amounts)February 28, 2021February 23, 2020February 28, 2021February 23, 2020
Numerator:
Net loss applicable to Common Stockholders$(5,498)$(11,518)$(29,799)$(23,042)
Denominator:
Weighted average shares for basic net loss per share29,323 29,170 29,282 29,155 
Effect of dilutive securities:
Stock options and restricted stock units
Weighted average shares for diluted net loss per share29,323 29,170 29,282 29,155 
Diluted net loss per share$(0.19)$(0.39)$(1.02)$(0.79)

Due to the Company’s net loss for the three and nine months ended February 28, 2021 and February 23, 2020, the net loss per share includes only weighted average shares outstanding. For the three and nine months ended February 28, 2021, the computation of the diluted net loss per share excludes the impact of options to purchase 2.4 million and 2.2 million shares of common stock, respectively, as such impacts would be antidilutive for these periods. For the three and nine months ended February 23, 2020, the computation of the diluted net loss per share excludes the impact of options to purchase 1.8 million and 2.2 million shares of common stock, respectively, as such impacts would be antidilutive for these periods.

5.    Income Taxes
The provision for income taxes for the nine months ended February 28, 2021 and February 23, 2020, was a benefit of $7.2 million and $7.8 million, respectively. The effective tax rate for the nine months ended February 28, 2021 and February 23, 2020 was 19.5% and 25%, respectively. The effective tax rate for the nine months ended February 28, 2021, was lower than the statutory federal income tax rate of 21% due to the income tax benefit on the increased forecasted losses, the generation of federal & state R&D credits and impact of states taxes, partially offset by the movement of the valuation allowance recorded against certain deferred tax assets.
As of February 28, 2021 and May 31, 2020, the Company had unrecognized tax benefits of $0.9 million and $0.8 million, respectively. Included in the balance of unrecognized tax benefits as of February 28, 2021 and May 31, 2020, is $0.9 million and $0.7 million, respectively, of tax benefits that, if recognized, would result in an adjustment to the Company’s effective tax rate. The Company managesdoes not expect its business operations through three strategic business unitsunrecognized tax benefits to change significantly within the next twelve months.
The Company has elected to classify interest and penalties related to uncertain tax positions as a component of its provision for income taxes. The Company has accrued an Other segment. Basedinsignificant amount of interest and penalties related to the income tax on the unrecognized tax benefits as of February 28, 2021 and May 31, 2020.
Due to tax attribute carryforwards, the Company is subject to examination for tax years 2017 forward for U.S. tax purposes. The Company is also subject to examination in various state jurisdictions for tax years 2015 forward, none of which were individually significant.

-18-

Table of Contents
6.    Debt
Long-term debt, net consists of the following:

(In thousands)February 28, 2021May 31, 2020
Term loan$150,000 $114,000 
Total principal amount of long-term debt150,000 114,000 
Less: unamortized debt issuance costs(4,949)(1,083)
Total long-term debt, net of unamortized debt issuance costs145,051 112,917 
Less: current portion of long-term debt, net(11,554)
Long-term debt, net$145,051 $101,363 

On September 23, 2016, the Company entered into a Credit Agreement (the "Credit Agreement") with JPMorgan, BMO Harris Bank N.A. ("BMO"), and City National Bank, as lenders (collectively, the “Lenders”), and JPMorgan as administrative agent, pursuant to which the Lenders provided the Company with a $100.0 million revolving line of credit (the “Revolver”) and a $50.0 million term loan facility (the “Term Loan”), guaranteed by each of the Company’s direct and indirect subsidiaries and secured by substantially all of the Company’s assets, with the exception of the Company’s investment in Windset. On October 25, 2019, the Company entered into the Sixth Amendment to the Credit Agreement, which among other things, increased the Term Loan to $120.0 million.
On July 15, 2020, the Company entered into the Eighth Amendment to the Credit Agreement (the “Eighth Amendment”), which among other things, (i) modified the definition of EBITDA to increase the limit on permitted exclusions for certain unusual, extraordinary or one-time cash items for each fiscal quarter ending on or after February 28, 2021, to a maximum of 20% of EBITDA, and (ii) restricted the Company from making Capital Expenditures over certain thresholds. Interest continues to be based on the Company’s Total Leverage Ratio, at a revised per annum Applicable Rate of either (i) the prime rate plus a spread of between 0.75% and 3.50% or (ii) the Eurodollar rate plus a spread of between 1.75% and 4.50%, plus, in each case, a commitment fee, as applicable, of between 0.15% and 0.55%, as further described in the Eighth Amendment.
Both the Revolver and the Term Loan were scheduled to mature on September 23, 2021, with the Term Loan requiring quarterly principal payments of $3.0 million and the remainder continuing to be due at maturity. The Credit Agreement contained customary financial covenants and events of default under which the obligation could be accelerated and/or the interest rate increased.

On December 31, 2020, the Company refinanced its existing Term Loan and Revolver by entering into two separate Credit Agreements (the "New Credit Agreements") with BMO and Goldman Sachs Specialty Lending Group, L.P. (“Goldman”) and Guggenheim Credit Services, LLC ("Guggenheim"), as lenders (collectively, the “Refinance Lenders”). Pursuant to the credit agreement related to the revolving credit facility, BMO has provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $75.0 million revolving line of credit (the “Refinance Revolver”) and serves as administrative agent of the Refinance Revolver. Pursuant to the credit agreement related to the term loan, Goldman and Guggenheim have provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $170.0 million term loan facility (split equally between Goldman and Guggenheim) (the “Refinance Term Loan”) and Goldman will serve as administrative agent of the Refinance Term Loan. The Refinance Revolver and Refinance Term Loan are guaranteed, and secured by, substantially all of the Company’s and the Company's direct and indirect subsidiaries' assets.

The Refinance Term Loan matures on December 31, 2025. The Refinance Revolver matures on December 31, 2025 or, if the Refinance Term Loan remains outstanding on such date, ninety (90) days prior to the maturity date of the Refinance Term Loan (on October 2, 2025).

The Refinance Term Loan provides for principal payments by the Company of 5% per annum, payable quarterly in arrears in equal installments, commencing on March 30, 2023, with the remainder due at maturity.

Interest on the Refinance Revolver is based upon the information reportedCompany’s average availability, at a per annum rate of either (i) LIBOR rate plus a spread of between 2.00% and 2.50% or (ii) base rate plus a spread of between 1.00% and 1.50%, plus a commitment fee, as applicable, of 0.375%. Interest on the Refinance Term Loan is at a per annum rate based on either (i) the base rate plus a spread of 7.50% or (ii) the LIBOR rate plus a spread of 8.50%.

-19-

Table of Contents
The New Credit Agreements provide the Company the right to increase the revolver commitments under the Refinance Revolver, subject to the satisfaction of certain conditions (including consent from BMO), by obtaining additional commitments from either BMO or another lending institution at an amount of up to $15.0 million.

The New Credit Agreements contains customary financial covenants and events of default under which the obligations thereunder could be accelerated and/or the interest rate increased in specified circumstances.

In connection with the New Credit Agreements, the Company incurred debt issuance costs from the lender and third-parties of $9.3 million.

Concurrent with the close of the New Credit Agreements, the Company repaid all outstanding borrowings under the current Credit Agreement, and terminated the Credit Agreement. In connection with the repayment of borrowings under the Credit Agreement, the Company recognized a loss in its third quarter of fiscal year 2021 of $1.1 million, as a result of the non-cash write-off of unamortized debt issuance costs related to the refinancing under the New Credit Agreements.
As of February 28, 2021, $41.0 million was outstanding on the Refinance Revolver, at an interest rate of 2.75%. As of February 28, 2021, the Refinance Term Loan had an interest rate of 9.5%. As of February 28, 2021, the Company was in compliance with all financial covenants and had no events of default under the New Credit Agreements.
Derivative Instruments
On November 1, 2016, the Company entered into an interest rate swap contract (the “2016 Swap”) with BMO at a notional amount of $50.0 million. The 2016 Swap had the effect of changing the Company’s previous Term Loan obligation from a variable interest rate to a fixed 30-day LIBOR rate of 1.22%.
On June 25, 2018, the Company entered into an interest rate swap contract (the “2018 Swap”) with BMO at a notional amount of $30.0 million. The 2018 Swap had the effect on our previous debt of converting the first $30.0 million of the total outstanding amount of the Company’s 30-day LIBOR borrowings from a variable interest rate to a fixed 30-day LIBOR rate of 2.74%.
On December 2, 2019, the Company entered into an interest rate swap contract (the "2019 Swap") with BMO at a notional amount of $110.0 million which decreases quarterly. The 2019 Swap had the effect on our previous debt of converting primarily all of the $110.0 million of the total outstanding amount of the Company's 30-day LIBOR borrowings from a variable interest rate to a fixed 30-day LIBOR rate of 1.526%.

7.    Business Segment Reporting
The Company operates using 3 strategic reportable business segments, aligned with how the Chief Executive Officer, who is the chief operating decision maker who is(“CODM”), manages the Chief Executive Officer,business: the Company has the following reportable segments: the Packaged Fresh VegetablesCuration Foods segment, the Food ExportLifecore segment, and the BiomaterialsOther segment.

The Packaged Fresh VegetablesCuration Foods segment marketsincludes (i) 4 natural food brands, including activities to market and packspack specialty packaged whole and fresh-cut fruitfruits and vegetables under the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store and food services industry. In addition, the Packaged Fresh Vegetables segment sells BreatheWay packaging to partners for fruit and vegetable products. The Food Export segment consists of revenues generated from the purchase andEat Smart or various private labels, sale of primarily whole commodity fruitpremium olive oil and vegetablevinegars under the O Olive Oil & Vinegar label, and the sale of avocado products predominantlyunder the Yucatan Foods and Cabo Fresh labels, (ii) BreatheWay® activities, and (iii) activity related to Asia. our 26.9% investment in Windset.
The BiomaterialsLifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. Other includes licensing and R&D activities from Landec’s Intelimer polymers for agricultural products, personal care products and other industrial products and from the operations of the O Olive business which was acquired on March 1, 2017.
The Other segment also includes corporate general and administrative expenses non-Packaged Fresh Vegetables(which includes costs associated with legal claims, including the Tanok compliance matters and non-Biomaterialsrelated litigation, and Pacific and Rancho litigation matter), non-Curation Foods and non-Lifecore interest expense, interest income, and income tax expenses. Corporate overhead is allocated between segments based on actual utilization and relative size.
All of the Company's assets of the Company are located within the United States of America.

America except for its Yucatan production facility located in Mexico.

-20-

Table of Contents
The Company’sCompany’s international sales by geography are based on the billing address of the customer and were as follows (in millions):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

November 26, 2017

  

November 27, 2016

 

Canada

 $17.5  $16.3  $35.7  $34.0 

Taiwan

 $7.5  $11.1  $11.3  $24.9 

Belgium

 $0.5  $1.6  $2.7  $6.9 

China

 $1.1  $6.3  $1.3  $11.4 

Indonesia

 $2.6  $3.6  $3.8  $5.1 

Japan

 $1.6  $2.9  $3.2  $4.9 

Philippines

 $0.4  $0.7  $1.0  $1.3 

All Other Countries

 $3.2  $3.5  $4.7  $5.7 

follows:

Three Months EndedNine Months Ended
(In millions)February 28, 2021February 23, 2020February 28, 2021February 23, 2020
Canada$14.8 $19.6 $45.6 $58.8 
Belgium6.0 9.3 12.6 12.4 
Czech Republic0.8 2.1 2.5 2.1 
Switzerland1.6 0.3 2.4 1.6 
United Kingdom1.2 0.2 2.4 0.7 
Ireland0.3 1.5 1.9 
All Other Countries1.8 0.1 2.7 1.0 

-16-
-21-

Table of Contents

Operations by business segment consisted of the following (in thousands):

Three Months Ended November 26, 2017

 

Packaged Fresh

Vegetables

  

Food

Export

  

Biomaterials

  

Other

  

Total

 

Net sales

 $107,152  $13,992  $14,113  $1,200  $136,457 

International sales

 $17,708  $13,992  $2,675  $41  $34,416 

Gross profit

 $9,445  $826  $5,217  $264  $15,752 

Net income (loss)

 $(270) $110  $1,260  $(613

)

 $487 

Depreciation and amortization

 $1,958  $  $910  $112  $2,980 

Dividend income

 $412  $  $  $  $412 

Interest income

 $18  $  $  $24  $42 

Interest expense, net

 $  $  $  $480  $480 

Income tax expense (benefit)

 $(95

)

 $31  $374  $(103

)

 $207 
                     

Three Months Ended November 27, 2016

                    

Net sales

 $97,978  $25,701  $11,931  $255  $135,865 

International sales

 $16,422  $25,701  $3,831  $  $45,954 

Gross profit

 $12,001  $1,850  $4,938  $164  $18,953 

Net income (loss)

 $(250

)

 $733  $1,312  $(469

)

 $1,326 

Depreciation and amortization

 $1,792  $2  $719  $37  $2,550 

Dividend income

 $412  $  $  $  $412 

Interest income

 $4  $  $  $  $4 

Interest expense (benefit), net

 $122  $  $(90

)

 $348  $380 

Income tax expense (benefit)

 $(142

)

 $207  $388  $240  $693 
                     

Six Months Ended November 26, 2017

                    

Net sales

 $209,720  $21,568  $26,277  $2,249  $259,814 

International sales

 $35,850  $21,568  $6,174  $73  $63,665 

Gross profit

 $24,460  $1,310  $8,739  $529  $35,038 

Net income (loss)

 $3,513  $(48

)

 $1,105  $(1,937

)

 $2,633 

Depreciation and amortization

 $3,930  $  $1,775  $229  $5,934 

Dividend income

 $825  $  $  $  $825 

Interest income

 $29  $  $  $45  $74 

Interest expense, net

 $  $  $  $884  $884 

Income tax expense (benefit)

 $1,002  $(14

)

 $347  $123  $1,458 
                     

Six Months Ended November 27, 2016

                    

Net sales

 $193,923  $49,040  $24,263  $1,033  $268,259 

International sales

 $34,266  $49,040  $10,873  $  $94,179 

Gross profit

 $26,407  $2,878  $10,060  $752  $40,097 

Net income (loss)

 $2,073  $928  $2,555  $(918

)

 $4,638 

Depreciation and amortization

 $3,612  $3  $1,431  $64  $5,110 

Dividend income

 $825  $  $  $  $825 

Interest income

 $7  $  $  $  $7 

Interest expense, net

 $671  $  $13  $348  $1,032 

Income tax expense

 $513  $262  $738  $1,069  $2,582 

following:


(In thousands)Curation FoodsLifecoreOtherTotal
Three Months Ended February 28, 2021
Net sales$110,557 $27,225 $$137,782 
Gross profit8,128 11,561 19,689 
Net (loss) income(5,615)5,104 (4,987)(5,498)
Depreciation and amortization2,994 1,385 22 4,401 
Dividend income281 281 
Interest income13 13 
Interest expense1,375 2,803 4,178 
Income tax (benefit) expense(1,773)1,612 (56)(217)
Corporate overhead allocation1,275 1,102 (2,377)
Nine Months Ended February 28, 2021
Net sales$332,080 $72,248 $$404,328 
Gross profit29,635 27,036 56,671 
Net (loss) income(26,268)9,708 (13,239)(29,799)
Depreciation and amortization9,310 4,055 76 13,441 
Dividend income844 844 
Interest income31 31 
Interest expense4,127 6,199 10,326 
Income tax (benefit) expense(8,296)3,066 (1,996)(7,226)
Corporate overhead allocation4,533 3,668 (8,201)
Three Months Ended February 23, 2020
Net sales$127,482 $25,446 $$152,928 
Gross profit9,162 10,885 20,047 
Net (loss) income(12,636)4,910 (3,792)(11,518)
Depreciation and amortization3,356 1,272 22 4,650 
Dividend income281 281 
Interest income46 46 
Interest expense1,376 835 2,211 
Income tax (benefit) expense(4,901)1,467 (1,876)(5,310)
Corporate overhead allocation1,401 1,043 (2,444)
Nine Months Ended February 23, 2020
Net sales$373,906 $60,329 $$434,235 
Gross profit28,874 22,023 50,897 
Net (loss) income(23,154)6,974 (6,862)(23,042)
Depreciation and amortization9,704 3,705 69 13,478 
Dividend income843 843 
Interest income31 65 96 
Interest expense4,128 2,327 6,455 
Income tax (benefit) expense(7,210)1,920 (2,550)(7,840)
Corporate overhead allocation4,510 2,979 (7,489)
-22-

Table of Contents
During the sixnine months ended November 26, 2017February 28, 2021 and November 27, 2016,February 23, 2020, sales to the Company’s top five customers accounted for 45%50% and 44%, respectively, of sales.sales, respectively. The Company’s top two customers, Walmart Stores, Inc. and Costco Wholesale Corporation, and Wal-Mart Stores, Inc., from the Packaged Fresh VegetablesCuration Foods segment, accounted for 16% and 15%, respectively, of revenues for the nine months ended February 28, 2021, and 18% and 17% of revenues,15%, respectively, for the sixnine months ended November 26, 2017,February 23, 2020.

8.    Restructuring Costs
During fiscal year 2020, the Company announced a restructuring plan to drive enhanced profitability, focus the business on its strategic assets and 17%redesign the organization to be the appropriate size to compete and 13% respectively,thrive. This includes a reduction-in-force, a reduction in leased office spaces, and the sale of non-strategic assets.
Asset write-off costs
Asset write-off costs are costs related to impairment or disposal of property and equipment as part of the Company's restructuring plan to drive enhanced profitability, focus the business on its strategic assets and redesign the organization to be the appropriate size to compete and thrive. These costs are included in Restructuring costs within the Consolidated Statements of Comprehensive (Loss) Income. See the Assets Held for Sale section within Note 1 for additional information.
In the sixfirst quarter of fiscal year 2021, the Company sold its interest in Ontario. The Company received net cash proceeds of $4.9 million in connection with the sale, and recorded a gain of $2.8 million.
In the first quarter of fiscal year 2021, the Company recognized an $8.8 million impairment loss related to its Hanover building and related assets which were sold in the second quarter of fiscal year 2021.
In the third quarter of fiscal year 2021, the Company recognized a $1.9 million impairment loss related to BreatheWay equipment as a result of a strategic shift in our BreatheWay business model driven by our restructuring plan.
Employee severance and benefit costs
Employee severance and benefit costs are costs incurred as a result of reduction-in-force driven by our restructuring plan and closure of offices and facilities. These costs were driven primarily by the closure of our San Rafael, California office, Santa Clara, California office, Los Angeles, California office, and the sale of our Hanover manufacturing facility.
Lease Costs
In August 2020, the Company closed its leased Santa Clara, California office and entered into a sublease agreement. In the fourth quarter of fiscal year 2020 the Company closed its leased Los Angeles, California office and plans to sublease the office.
Other restructuring costs
For the three and nine months ended November 27, 2016. The Company expects that, for the foreseeable future, a limited number of customers may continueFebruary 28, 2021, other restructuring costs primarily related to account for a significant portion of its revenues.

10.

Subsequent Events

On December 22, 2017, the U.S. Government enacted the reconciled tax reform bill, commonly known as the Tax Cuts and Jobs Act of 2017 (the “TCJA”), which became effective on January 1, 2018. Among other tax related changes,consulting costs to execute the Company’s federal statutory tax rate willrestructuring plan to drive enhanced profitability, focus the business on its strategic assets, and redesign the organization to be reduced from 35%,the appropriate size to an average rate of 29% forcompete and thrive.

The following table summarizes the fiscal year ended May 27, 2018, and then 21% for fiscal years thereafter. Additionally, as of November 26, 2017, the Company had a deferred tax liability of $26.0 million based on a U.S. federal tax rate of 35%. Given the reduction in the U.S. corporate statutory tax rate, the Company will remeasure its deferred tax liability and anticipates a $7 million to $9 million benefit to its income tax expense with a corresponding reduction to its deferred tax liability. This impact will berestructuring costs recognized in the Company’s third fiscal quarterConsolidated Statements of 2018, which is the period the TCJA was enacted.

(Loss) Income, by Business Segment:

(in thousands)Curation FoodsLifecoreOtherTotal
Three Months Ended February 28, 2021
Asset write-off costs$1,877 $$$1,877 
Employee severance and benefit costs315 315 
Lease costs
Other restructuring costs393 115 508 
Total restructuring costs$2,585 $$115 $2,700 

-17-
-23-

Table of Contents

Curation FoodsLifecoreOtherTotal
Nine Months Ended February 28, 2021
Asset write-off costs$7,882 $$$7,882 
Employee severance and benefit costs1,430 1,430 
Lease costs
Other restructuring costs2,536 918 3,454 
  Total restructuring costs$11,848 $$918 $12,766 

The following table summarizes the restructuring costs recognized in the Company’s Consolidated Statements of (Loss) Income, by Business Segment, since inception of the restructuring plan in fiscal year 2020 through the nine months ended February 28, 2021:

Curation FoodsLifecoreOtherTotal
(in thousands)
Asset write-off costs, net$20,544 $$418 $20,962 
Employee severance and benefit costs2,899 784 3,683 
Lease costs392 26 418 
Other restructuring costs3,5591,4294,988
Total restructuring costs$27,394 $$2,657 $30,051 

The total expected cost related to the restructuring plan is approximately $32.0 million.

9.     Subsequent Events
COVID-19 Pandemic
There are many uncertainties regarding the current novel coronavirus (“COVID-19”) pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic, and the extent of local and worldwide social, political, and economic disruption it may cause. The COVID-19 pandemic as well as the actions taken in response to the pandemic, have had, and we believe will continue to have, significant adverse impacts on many aspects of the Company’s operations, directly and indirectly, including with respect to sales, customer behaviors, transportation costs, business and manufacturing operations, inventory, the Company’s employees, and the market generally, and the scope and nature of these impacts continue to evolve each day. The Company expects to continue to assess the evolving impact of the COVID-19 pandemic, and intends to continue to make adjustments to its responses accordingly.
-24-

Table of Contents

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the unaudited consolidated financial statements and accompanyingaccompanying notes included in Part I, Item 1, of this Form 10-Q and the audited consolidated financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Landec’s Annual Report on Form 10-K for the fiscal year ended May 28, 2017.

Except for the historical information contained herein, the matters discussed in this report are31, 2020.

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements withinregarding future events and our future results that are subject to the meaningsafe harbor created under the Private Securities Litigation Reform Act of Section 21E1995 and other safe harbors under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934. These1934, as amended (the “Exchange Act”). Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certainare subject to risks and uncertainties that couldmay cause actual results to differ materially from those in the forward-looking statements.that we expected. Potential risks and uncertainties include, without limitation, the timing and expenses associated with operations, the ability to achieve acceptance of our new products in the market place, weather conditions that can affect the supply and price of produce, government regulations affecting our business, uncertainties related to COVID-19 and the impact of our responses to it, the timing of regulatory approvals, the ability to successfully integrate Yucatan Foods into the Curation Foods business, the mix between domestic and international sales, and those other risks mentioned in this Form 10-Qreport and those mentioned in Landec’sour Annual Report on Form 10-K for the fiscal year ended May 28, 2017. Landec undertakes31, 2020.
We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Accordingly, our actual results could differ materially from those projected in the forward-looking statements for many reasons, including the risk factors listed in Item 1A. “Risk Factors” and in our Annual Report on Form 10-K for the fiscal year ended May 31, 2020.
All forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements as well as others made in this report, our Annual Report on Form 10-K for the fiscal year ended May 31, 2020, and hereafter in our other SEC filings and public communications.
You should evaluate all forward-looking statements made by us in the context of all risks and uncertainties described with respect to our business. We caution you that the risks and uncertainties identified by us may not be all of the factors that are important to you. Furthermore, the forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements in order to reflectstatement as a result of new information, future events or circumstances that may arise after the date of this report.

otherwise, except as otherwise required by law.


Critical Accounting Policies and Use of Estimates

There have been no material changes to the Company's critical accounting policies which are included and describeduse of estimates from those disclosed in the Company’s Form 10-K for thethe fiscal year ended May 28, 2017 filed with31, 2020. For a discussion of our critical accounting policies and use of estimates, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates in Part II, Item 7 of the Securities and Exchange CommissionCompany’s Annual Report on August 10, 2017.

SeeForm 10-K for the fiscal year ended May 31, 2020.


Recently Issued Accounting Pronouncements
The Company is subject to several recently issued accounting pronouncements. Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements of the Notes to the Consolidated Financial Statements for a discussionwhich is contained in Part I, Item 1 of recentthis Quarterly Report on Form 10-Q, describes these new accounting guidance not yet adopted.

pronouncements and is incorporated herein by reference.


-25-

Table of Contents
The Company


Corporate Overview
Landec Corporation and its subsidiaries (“Landec”Landec,” the “Company”, "we" or the “Company”"us") design, develop, manufacture, and sell differentiated health and wellness products for food and biomaterials markets. There continuesmarkets, and license technology applications to be a dramatic shift in consumer behaviorpartners.
Landec’s natural food company, Curation Foods, Inc. (“Curation Foods”) is focused on innovating and distributing plant-based foods with 100% clean ingredients to healthier eating habitsretail, club and preventive wellnessfoodservice channels throughout North America. Curation Foods is able to improve quality of life. In our Apio, Inc. (“Apio”) Packaged Fresh Vegetable business, we are committed to offering healthy, fresh produce products conveniently packaged to consumers. Apio also exports whole fruit and vegetables, predominantly to Asiamaximize product freshness through its subsidiary, Cal-Ex Trading Company (“Cal-Ex”). In ourgeographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology.
Landec’s biomedical company, Lifecore Biomedical, Inc. (“Lifecore”) biomaterials, is a fully integrated CDMO that offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
Landec was incorporated in California on October 31, 1986 and reincorporated as a Delaware corporation on November 6, 2008. Landec’s common stock is listed on The NASDAQ Global Select Market under the symbol “LNDC”. The Company’s principal executive offices are located at 2811 Airpark Drive Santa Maria, California 93455, and the telephone number is (650) 306-1650.
Reportable Segments
Landec has three reportable business we commercialize products that enable people to staysegments – Curation Foods, Lifecore and Other, which are described below.
Curation Foods
Curation Foods Overview
Based in Santa Maria, California, Curation Foods’ primary business is the processing, marketing and selling of fresh packaged plant based salads and vegetables. Curation Foods serves as the corporate umbrella for its patented BreatheWay® packaging technology and for its portfolio of four natural food brands, including the Company’s legacy and flagship brand Eat Smart® as well as its three more active as they grow older. In our recently acquired natural food brands, O Olive Oil Inc.& Vinegar® (“O Olive”) business acquired on March 1, 2017, we sell premium California sourced specialty olive oilsproducts, and wine vinegarYucatan® and Cabo Fresh authentic guacamole and avocado products.

Landec’s Packaged Fresh Vegetables The major distinguishing characteristics of Curation Foods that provide a competitive advantage are its insight-driven product innovation, diversified fresh food supply chain, refrigerated supply chain and Biomaterials businesses utilize polymer chemistry technology,customer reach. We believe that Curation Foods is well positioned as a key differentiating factor. Both businesses focus on business-to-business selling such as selling directly tosingle source supplier of a broad range of products. Curation Foods also has three East Coast processing facilities and five East Coast distribution centers for nationwide delivery of its packaged salads and vegetable products. As of May 31, 2020, our products were available in over 86% of retail grocery store chains and club stores across North America.

During fiscal 2019, the Company redefined the strategy for Apioits Curation Foods segment in order to improve the Company’s overall profitability by launching Project SWIFT, a value creation program designed to transform the Curation Foods business by simplifying the business, realigning its resources and directlyseeking to partnersimprove the Company’s balance sheet through three strategic priorities - optimizing its operations networks, maximizing strategic assets and redesigning the organization to be more competitive.
Curation Foods Brands
Eat Smart: The Company sells specialty fresh packaged Eat Smart branded and private label salads, fresh-cut vegetables and whole produce to retailers, club stores, and food service operators, primarily in the medical deviceUnited States and pharmaceutical markets, with a concentration in ophthalmology for Lifecore.

Landec has three operating segments – Packaged Fresh Vegetables, Food Export and Biomaterials, each of which is described below and an Other segment. The results of the O Olive business are included in the Other segment in fiscal year 2018 because they are not significant to Landec’s overall results for fiscal year 2018. Financial information concerning each of these segments is summarized in Note 9 – Business Segment Reporting.

Apio operates the Packaged Fresh Vegetables business, which combines our proprietary BreatheWay® food packaging technology with the capabilities of a large national food supplier and value-added produce processor which sells products underCanada. Within the Eat Smart®Smart brand, to consumers and the GreenLine® brand to foodservice operators, as well as under private labels. In Apio’s Packaged Fresh Vegetables operations, produce is processed by trimming, washing, sorting, blending, and packaging into bags and traystrays.

O Olive Oil & Vinegar: The Company acquired O on March 1, 2017. O, founded in 1995, is based in Petaluma, California, and is the premier producer of California specialty olive oils and wine vinegars. Its products are sold in natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.
-26-

Table of Contents
Yucatan & Cabo Fresh Avocado Products: The Company acquired Yucatan Foods on December 1, 2018. Yucatan Foods was founded in 1991. As part of the acquisition of Yucatan Foods, Curation Foods acquired the newly built production facility in Guanajuato, Mexico. The Yucatan Foods business added a double-digit growth platform, a lower-cost infrastructure in Mexico, and higher margin product offerings that in most cases incorporate Landec’sgenerally exhibit less sourcing volatility. The Company manufactures and sells Yucatan and Cabo Fresh guacamole and avocado food products primarily to the U.S. grocery channel, but also to the U.S. mass retail, Canadian grocery retail and foodservice channels.
BreatheWay Packaging Technology: The Company’s BreatheWay membrane technology.technology establishes a beneficial packaging atmosphere adapting to changing fresh product respiration and temperature in order to extend freshness naturally. The BreatheWay membrane increasessupply chain packaging technology extends shelf-life and reduces shrink (waste) for retailers and helps to ensure that consumers receive fresh produce by the time the product makes its way through the distribution chain. Apio alsochain to the consumer. The Company generates revenue from the sale to and/or use of its BreatheWay patented packaging technology by partners such as ChiquitaBrands International, Inc. (“Chiquita”)Windset, for packaging and distribution of bananas and berries and Windset Holding 2010 Ltd., a Canadian corporation (“Windset”), for packaging ofits greenhouse grown cucumbers and peppers.

-18-

Apio also operates the Food Export business. The Food Export business purchases and sells wholeproduct ensuring more marketable fruit and vegetable commodities predominantly to Asian markets.

Lifecore operates our Biomaterials business and is involved in the development and manufacture of pharmaceutical-grade sodium hyaluronate (“HA”) products and providing contract development and aseptic manufacturing services. Sodium hyaluronate is a naturally occurring polysaccharide that is widely distributed in the extracellular matrix in animals and humans. Based upon Lifecore’s expertise working with highly viscous HA, the Company specializes in fermentation and aseptic formulation, filling, and packaging services, as a contract development and manufacturing organization (“CDMO”), for difficult to handle (viscous) medicines filled in finished dose vials and syringes.

O Olive was acquired on March 1, 2017. O Olive, founded in 1995, is based in Petaluma, California, and is a premier producer of California specialty olive oils and wine vinegars. Its products are sold in over 4,600 natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.

Landec was incorporated in California on October 31, 1986 and reincorporated as a Delaware corporation on November 6, 2008. Our common stock is listed on The NASDAQ Global Select Market under the symbol “LNDC”. The Company’s principal executive offices are locatedvegetables at 5201 Great America Parkway, Suite 232, Santa Clara, California 95054, and the telephone number is (650) 306-1650.

Description of Core Business

Landec operates its business in three core business segments: Packaged Fresh Vegetables, Food Export and Biomaterials, and it has an Other segment.  

Packaged Fresh Vegetables Business

Based in Guadalupe, California, Apio’s primary business is fresh-cut and whole vegetable products primarily packaged in proprietary BreatheWay packaging. The Packaged Fresh Vegetables business markets a variety of fresh-cut and whole vegetables to the top retail grocery chains, club stores, and food service operators. During the fiscal year ended May 28, 2017, Apio shipped approximately 26 million cartons of produce to its customers throughout North America, primarily in the United States.

There are four major distinguishing characteristics of Apio that provide competitive advantages in the Packaged Fresh Vegetables market:

(1)

Packaged Vegetables Supplier: Apio has structured its business as a marketer and seller of branded and private label blended, fresh-cut and whole vegetable products. It is focused on selling products primarily under its Eat Smart brand, with some sales under its GreenLine brand and private label brands. As retail grocery chains, club stores and food service operators consolidate, Apio is well positioned as a single source of a broad range of products.

(2)

Nationwide Processing and Distribution: Apio has strategically invested in its Packaged Fresh Vegetables business. Apio’s largest processing plant is in Guadalupe, CA, and is automated with state-of-the-art vegetable processing equipment in one of the lowest cost, growing regions in California, the Santa Maria Valley. With the acquisition of GreenLine in 2012, Apio added three East Coast processing facilities and five East Coast distribution centers for nationwide delivery of all of its packaged vegetable products in order to meet the next-day delivery needs of customers.

(3)

Expanded Product Line Using Technology and Unique Blends: Apio, through the use of its BreatheWay packagingtechnology, is introducing new packaged vegetable products each year. These new product offerings range from various sizes of fresh-cut bagged products, to vegetable trays, to whole produce, to vegetable salads and to snack packs.

(4)

Products Currently in Approximately 70% of North American Retail Grocery Stores: Apio has products in approximately 70% of all North American retail grocery stores. This gives Apio the opportunity to sell new products to existing customers and to increase distribution of its approximately 120 unique products within those customers.

retail. Most vegetable products packaged in Apio’s BreatheWay packaging have an approximate 17 day shelf-life. In addition to packaging innovation, Apio has developed innovative blends and combinations of vegetables that are sold in flexible film bags or rigid trays. More recently, Apio has launched a family of salad kits that are comprised of “superfood” mixtures of vegetables with healthy toppings and dressings. The first salad kit to launch under the Eat Smart® brand was Sweet Kale Salad, which now has significant distribution throughout club and retail stores in North America. Additionally, we have launched under the Eat Smart brand several other superfood salad kits including Wild Greens and Quinoa, Beets and Greens, Southwest Salad, and Asian Sesame and more recently a new line of single serve salads under our new Salad Shake-Ups!™ brand. The Company’s expertise includes accessing leading culinary experts and nutritionists nationally to help in the new product development process. We believe that the Company’s new products are “on trend” and strong market acceptance supports this belief. Recent statistics show that more than two-thirds of adults are considered to be overweight or obese and more than one-third of adults are considered to be obese. More and more consumers are beginning to make better food choices in their schools, homes, and in restaurants and that is where the superfood products can fit into consumers’ daily healthy food choices.

-19-

In addition to proprietary packaging technology and a strong new product development pipeline, the Company has strong channels of distribution throughout North America with retail grocery store chains and club stores. Landec has one or more of its products in approximately 70% of all retail and club store sites in the U.S. giving it a strong platform for introducing new products.

The Company sells its products under its nationally-known brand Eat Smart to retail and club stores and its GreenLine brand to foodservice operators. The Company also periodically licenses its BreatheWay packaging technology to partners such as Chiquita for packaging bananas and berries, and Windset for packaging peppers and cucumbers that are grown hydroponically in greenhouses.achieve a shelf-life of approximately 17 days. These packaging license relationships generate revenues either from product sales or royalties once commercialized. The Company is engaged in the testing and development of other BreatheWay products. LandecThe Company manufactures its BreatheWay packaging through selected qualified contract manufacturers.

Windset

: The Company holds a 26.9% noncontrolling investment ownership in Windset, a leading-edge grower of hydroponically grown produce. The Company believes that hydroponically-grown produce using Windset’sWindset’s know-how and growing practices of hydroponically grown produce will result in higher yields with competitive growing costs that will provide dependable year-round supply to Windset’s customers. In addition, the produce grown in Windset’s greenhouses uses significantly less water than field grown crops and has a very high safety profile as no soil is used in the growing process. Windset owns and operates greenhouses in British Columbia, Canada and in Nevada and California. In addition to growing produce in its own greenhouses, Windset has numerous marketing arrangements with other greenhouse growers and utilizes buy/sell arrangements to meet fluctuation in demand from their customers.

On March 15, 2017, The Curation Foods segment operating results include the Companydividends and Windset agreed to extend their relationship through March 31, 2022.

See Note 3 – Investment in Non-public CompanyLandec’s share of the Notes to Consolidated Financial Statements for a discussion about the Company’s 26.9% minority ownership interestchange in Windset.

Food Export Business

Food Export revenues consistfair market value of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products primarily to Asia through Apio’s export company, Cal-Ex. The Food Export businessits investment in Windset.

Lifecore Biomedical
Lifecore, located in Chaska, Minnesota, is a buy/sell businessfully integrated CDMO that realizes an average gross margin from 5-10%.

Biomaterials Business

offers highly differentiated capabilities in the development, fill and finish of sterile, injectable pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (“HA”) in bulk form as well as formulated and filled syringes and vials for injectable products used in treating a broad spectrum of medical conditions and procedures. Lifecore uses its fermentation process and aseptic formulation and filling expertise to be a leader in the development of HA-based products for multiplemultiple applications and to take advantage of non-HA device and drug opportunities which leverage its expertise in manufacturing and aseptic syringe filling capabilities. Elements

Lifecore provides product development services as a CDMO to assist its customers in obtaining regulatory approval for the commercial sale of their drug product. These services include activities such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation and production of materials for use within clinical studies.
Built over many years of experience, Lifecore separates itself from its competition based on its five areas of expertise, including but not limited to Lifecore’s strategy includeability to:
Establish strategic relationships with market leaders:
Lifecore continues to develop applications for products with partners who have strong marketing, sales, and distribution capabilities to end-user markets. Through its strong reputation and history of providing pharmaceutical grade HA and products, Lifecore has established long-term relationships with global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories, and leverages those partnerships to attract new relationships in other medical markets.
Expand medical applications for HA:
Due to the following:

(1)

Establish strategic relationships with market leaders:Lifecore will continue to develop applications for products with partners who have strong marketing, sales, and distribution capabilities to end-user markets. Through its strong reputation and history of providing pharmaceutical grade HA and products, Lifecore has been able to establish long-term relationships with the market leading ophthalmic surgical companies, and leverages those partnerships to attract new relationships in other medical markets.

(2)

Expand medical applications for HA: Due to the growing knowledge of the unique characteristics of HA, and the role it plays in normal physiology, Lifecore continues to identify opportunities for the use of HA in other medical applications, such as wound care, aesthetic surgery, drug delivery, device coatings, and through pharmaceutical sales to academic and corporate research customers.

(3)

Utilize manufacturing infrastructure to pursue contract aseptic filling and fermentation opportunities: Lifecore has made strategic capital investments in its contract manufacturing and development business focusing on extending its aseptic filling capacity and capabilities. It is investing in this segment to meet increasing partner demand and attract new contract filling opportunities. Lifecore is using its manufacturing capabilities to provide contract manufacturing and development services to its partners in the area of sterile pre-filled syringes and fermentation and purification requirements.

growing knowledge of the unique characteristics of HA and Lifecore’s unique strength and history as a trusted manufacturer of pharmaceutical injectable grade HA products, Lifecore continues to identify and pursue opportunities for the use of HA in other medical applications, such as wound care, aesthetic surgery, drug delivery, next generation orthopedics and device coatings, and through sales to academic and corporate research customers. Further applications may involve expanding process development activity and/or additional licensing of technology.
-20-
-27-

Table of Contents

(4)

Maintain flexibility in product development and supply relationships:Lifecore’s vertically integrated development and manufacturing capabilities allow it to establish a variety of contractual relationships with global corporate partners. Lifecore’s role in these relationships extends from supplying HA raw materials to providing tech transfer and development services to manufacturing aseptically-packaged, finished sterile products, and to assuming full supply chain responsibilities.

Utilize manufacturing infrastructure to meet customer demand:
Lifecore has made strategic capital investments in its CDMO business focusing on extending its aseptic filling capacity and capabilities to meet increasing partner demand and to attract new contract filling opportunities outside of HA markets. Lifecore is using its manufacturing capabilities to provide contract manufacturing and development services to its partners in the area of sterile pre-filled syringes and vials, as well as fermentation and purification requirements.
Maintain flexibility in product development and supply relationships:
Lifecore’s vertically integrated development and manufacturing capabilities allow it to establish a variety of contractual relationships with global corporate partners. Lifecore’s role in these relationships extends from supplying HA raw materials to providing technology transfer and development services to manufacturing aseptically filled, finished sterile products, and assuming full supply chain responsibilities.
Deliver consistent quality:
Lifecore has built a world class quality and regulatory system that is demonstrated in their results, processes and customer relationships. With over 35 years of a superior track record with global regulatory bodies (FDA, EMA, ANVISA, etc.), Lifecore is the partner of choice for companies looking for proven experience in delivering QbD, cGMP compliance, and manufacturing excellence with pharmaceutical elegance and quality. Lifecore’s world class quality and regulatory system and excellent track record with the global regulatory bodies ensure partners that they will safely bring innovative therapies to market.
Other

Included in the Other segment is Corporate, which includes corporate general and O Olive.administrative expenses, non-Curation Foods and non-Lifecore interest income and income tax expenses.
COVID-19 Pandemic
There are many uncertainties regarding the current novel coronavirus (“COVID-19”) pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic, and the extent of local and worldwide social, political, and economic disruption it may cause. The COVID-19 pandemic as well as the actions taken in response to the pandemic, have had, and we believe will continue to have, significant adverse impacts on many aspects of the Company’s operations, directly and indirectly, including with respect to sales, customer behaviors, transportation costs, business and manufacturing operations, inventory, the Company’s employees, and the market generally, and the scope and nature of these impacts continue to evolve each day. The Company acquired O Olive on March 1, 2017. O Olive, founded in 1995, is based in Petaluma, California,expects to continue to assess the evolving impact of the COVID-19 pandemic, and is the premier producer of California specialty olive oils and wine vinegars. Its products are sold in over 4,600 natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.

intends to continue to make adjustments to its responses accordingly.


Results of Operations

Revenues(in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

Change

  

November 26, 2017

  

November 27, 2016

  

Change

 

Packaged Fresh Vegetables

 $107,152  $97,978   9

%

 $209,720  $193,923   8

%

Food Export

  13,992   25,701   (46

%)

  21,568   49,040   (56

%)

Total Apio

  121,144   123,679   (2

%)

  231,288   242,963   (5

%)

Biomaterials

  14,113   11,931   18

%

  26,277   24,263   8

%

Other

  1,200   255   371

%

  2,249   1,033   118

%

Total Revenues

 $136,457  $135,865   0

%

 $259,814  $268,259   (3

%)

Packaged Fresh Vegetables (Apio)

Apio’s Packaged Fresh Vegetables

Curation Foods revenues consist of revenues generated from (1) the sale of specialty packaged fresh-cut and whole processed vegetable products and salads that are washed and packaged in Apio’smost cases in the Company’s proprietary BreatheWay packaging and sold primarily under the Eat Smart and GreenLine brandsbrand and various private labels.labels, (2) O Olive oils and wine vinegars, and (3) Yucatan and Cabo Fresh branded guacamole and avocado products. In addition, the Packaged Fresh Vegetables revenues includeCuration Foods reportable business segment includes the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position and from the sale of BreatheWay packaging to license partners.

Lifecore generates revenues from the development and manufacture of HA products and providing contract development and aseptic manufacturing services to customers. Lifecore generates revenues from two integrated activities: (1) CDMO and (2) fermentation.

(In thousands)Three Months EndedChangeNine Months EndedChange
February 28, 2021February 23, 2020Amount%February 28, 2021February 23, 2020Amount%
Curation Foods$110,557 $127,482 $(16,925)(13)%$332,080 $373,906 $(41,826)(11)%
Lifecore27,225 25,446 1,779 %72,248 60,329 11,919 20 %
Total Revenues$137,782 $152,928 $(15,146)(10)%$404,328 $434,235 $(29,907)(7)%

-28-

Table of Contents
Curation Foods
The increasedecrease in Apio’s Packaged Fresh VegetablesCuration Foods’ revenues for the three and six months ended November 26, 2017February 28, 2021, compared to the same periodsperiod last year, was primarily due to a 5% increase$16.2 million decrease in unit volume sales with all of the increasefresh packaged salads and vegetables segment, which is primarily due to a (1) $10.5 million planned shift away from non-strategic revenue streams, including packaged vegetables in bags and trays, and (2) a $4.1 million decrease in green bean revenues comingdriven by a decrease in demand from increased sales of our salad products which are higher priced products compared tofood service customers during the Company’s lower priced core products whose sales were essentially flatCOVID-19 pandemic.
The decrease in Curation Foods’ revenues for the three and sixnine months ended November 26, 2017February 28, 2021, compared to the same periods last year.

Food Export (Apio)

Apio’s Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia by Cal-Ex. Apio records revenue equal to the sale price to third parties because it takes title to the product while in transit.

The decrease in Apio’s Food Export revenues for the three and six months ended November 26, 2017 compared to the same periodsperiod last year, was primarily due to a 49% and 58%, respectively,$42.3 million decrease in unit volume salesthe fresh packaged salads and vegetables segment, which is primarily due to the Company’s strategic decision during fiscal year 2017 to discontinue its lower-margin export fruit business, a large majority of which is typically sold(1) $24.1 million planned shift away from non-strategic revenue streams, including packaged vegetables in bags and trays, (2) a $11.6 million decrease in green bean revenues driven by a decrease in demand from food service customers during the first half of our fiscal year.

-21-

Biomaterials (Lifecore)

Lifecore principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 65% of Lifecore’s revenues in fiscal year 2017, (2) Orthopedic, which represented approximately 15% of Lifecore’s revenues in fiscal year 2017,COVID-19 pandemic, and (3) Other/Non-HA products, which represented approximately 20% of Lifecore’sa $3.2 million decrease in salad revenues driven by a decrease in fiscal year 2017.

demand during the COVID-19 pandemic.

Lifecore
The increase in Lifecore’s revenues for the three months ended November 26, 2017February 28, 2021, compared to the same period last year, was due to a $1.8$4.6 million increase in business developmentCDMO revenues primarily from new customers and a $830,000an increase in aseptic filling revenues due to new commercial aseptic business and an increase in sales toshipments, resulting from increased demand from existing customers, partially offset by a $489,000$2.8 million decrease in fermentation sales primarily due primarily to the timing of shipments withincustomer orders and the fiscal year.

related shipments.

The increase in Lifecore’s revenues for the sixnine months ended November 26, 2017February 28, 2021, compared to the same period last year, was due to a $2.2$10.2 million increase in business developmentCDMO revenues primarily from new customers and a $3.5 millionan increase in aseptic filling revenues due to new commercial aseptic business and an increase in sales toshipments, resulting from increased demand from existing customers, partially offset byand a $3.7$1.7 million decreaseincrease in fermentation sales primarily due primarily to the timing of shipments withincustomer orders and the fiscal year.

Other

Other revenues for the three and six months ended November 27, 2016 are generated from the licensing agreements with corporate partners and for the three and six months ended November 26, 2017 from the sale of olive oils and vinegars by O Olive.

The increase in Other revenues for the three and six months ended November 26, 2017 compared to the same periods last year was due to $1.2 million and $2.2 million, respectively, of revenues from O Olive that was acquired on March 1, 2017 compared to $255,000 and 1.0 million, respectively, in revenues for the three and six months ended November 27, 2016 from two license agreements that were completed in August 2016 and December 2016, respectively.

related shipments.


Gross Profit(in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

Change

  

November 26, 2017

  

November 27, 2016

  

Change

 

Packaged Fresh Vegetables

 $9,445  $12,001   (21

%)

 $24,460  $26,407   (7

%)

Food Export

  826   1,850   (55

%)

  1,310   2,878   (54

%)

Total Apio

  10,271   13,851   (26

%)

  25,770   29,285   (12

%)

Biomaterials

  5,217   4,938   6

%

  8,739   10,060   (13

%)

Corporate

  264   164   61

%

  529   752   (30

%)

Total Gross Profit

 $15,752  $18,953   (17

%)

 $35,038  $40,097   (13

%)

General

There are numerous factors that can influence gross profit including product mix, customer mix, manufacturing costs, volume, sales discounts and charges for excess or obsolete inventory, to name a few. Many of these factors influence or are interrelated withwith other factors. The Company includes in cost of sales all of the costs related to the sale of products in accordance with GAAP. These costs include the following:following costs: raw materials (including produce, seeds, packaging, syringes and fermentation and purification supplies), direct labor, overhead (including indirect labor, depreciation, and facility-related costs) and shipping and shipping-related costs. The following are the primary reasons for the changes in gross profit for the three and six months ended November 26, 2017 compared to the same period last year as outlined in the table above.

Packaged Fresh Vegetables (Apio)

The decrease in gross profit for Apio’s Packaged Fresh Vegetables business for the three and six months ended November 26, 2017 compared to the same periods last year was primarily due to $3.9 million of incremental produce sourcing costs during the second fiscal quarter of 2018 resulting from hurricanes and tropical storms which negatively impacted produce yields and quality. These incremental produce sourcing costs were partially offset by gross profit on higher salad sales.


-22-
(In thousands)Three Months EndedChangeNine Months EndedChange
February 28, 2021February 23, 2020Amount%February 28, 2021February 23, 2020Amount%
Curation Foods$8,128 $9,162 $(1,034)(11)%$29,635 $28,874 $761 %
Lifecore11,561 10,885 676 %27,036 22,023 5,013 23 %
Total Gross Profit$19,689 $20,047 $(358)(2)%$56,671 $50,897 $5,774 11 %

Table of Contents
Curation Foods

Food Export (Apio)

Apio’s Food Export business is a buy/sell business that realizes an average gross margin from 5-10%.

The decrease in gross profit for Apio’s Food Exportthe Curation Foods business during the three and six months ended November 26, 2017 compared to the same periods last year was primarily due to a 46% and 56%, respectively, decrease in revenues due to transitioning away from low-margin export fruit business.

Biomaterials (Lifecore)

The increase in Lifecore’s gross profit for the three months ended November 26, 2017February 28, 2021, compared to the same period last year, was lower than the 18% increase in revenues primarily due to the timinga decrease in royalty revenue of production within the$1.6 million due to nonrecurring royalty transactions, which was partially offset by an increase in gross profits from avocado products due to lower avocado costs in fiscal year which resulted in the absorption of overhead into inventory being lower in the second quarter of fiscal year 20182021 compared to the same period last year.

fiscal 2020.

The decreaseincrease in Lifecore’s gross profit for the sixCuration Foods business for the nine months ended November 26, 2017February 28, 2021, compared to the same period last year, was a result ofprimarily due to an unfavorable product mix changeincrease in gross profits from avocado products due to a higher percentage of revenues coming fromselling products in fiscal 2021 produced with lower margin aseptically filled product sales than from higher margin fermentation sales during the same period last year. Gross profit also decreased because of the timing of production and thus overhead absorption within thecost avocados compared to fiscal year.  These decreases were2020, which was partially offset by (1) the decrease in gross profit realized on higher revenues.

Other

profits primarily driven by the decrease in revenues from our planned shift away from non-strategic fresh packaged salads and vegetables segment revenue streams, primarily packaged vegetables in bags and trays, (2) the decrease in gross profits driven by a decrease in royalty revenue of $1.6 million due to nonrecurring royalty transactions, and (3) business interruption insurance recoveries received in fiscal year 2020.

-29-

Table of Contents
Lifecore
The increase in Other gross profit for the Lifecore business for the three and nine months ended November 26, 2017February 28, 2021, compared to the same period last year, was due primarily to the $264,000 of gross profit for the three months ended November 26, 2017 from O Olive (which was acquired on March 1, 2017) being more than the gross profit from two license agreements for the same period last year because one of the licensing agreements was completed in the first quarter (August) of last year and therefore generated noincreased revenue, during the second quarter of last year and the other was completed during early in the third quarter (December) of last year.

The decrease in Other gross profit for the six months ended November 26, 2017 compared to the same period last year was due to the $529,000 of gross profit for the six months ended November 26, 2017 from O Olive (which was acquired on March 1, 2017) being less than the gross profit from two license agreements for the same period last year which were completed in August 2016 and December 2016, respectively.

as well as a favorable sales mix.

Operating Expenses (in thousands):

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

Change

  

November 26, 2017

  

November 27, 2016

  

Change

 

Research and Development:

                        

Apio

 $1,457  $286   409

%

 $2,466  $523   372

%

Lifecore

  1,334   1,333   0

%

  2,702   2,665   1

%

Other

  581   346   68

%

  923   715   29

%

Total R&D

  3,372   1,965   72

%

  6,091   3,903   56

%

                         

Selling, General and Administrative:

                     

Apio

  8,505   9,788   (13

%)

  17,340   19,349   (10

%)

Lifecore

  1,428   1,304   10

%

  2,943   2,710   9

%

Other

  3,001   2,632   14

%

  6,696   5,401   24

%

Total SG&A

 $12,934  $13,724   (6

%)

 $26,979  $27,460   (2

%)

Expenses:

Research and Development

Landec’s Research and Development (“

R&D”) consisted&D expenses consist primarily of product development and commercialization initiatives. R&D efforts at Apioexpenses in our Curation Foods business are primarily focused on newinnovating our current product innovationlines and on the Company’s proprietary BreatheWay membranes used for packaging produce, with a focus on extending the shelf-life of sensitive vegetables and fruit. In the Lifecore business, the R&D effortsexpenses are focused on new products and applications for HA-based and non-HA biomaterials. For Other, the R&D effortsexpenses are primarily focused on supporting the developmentcreating and commercializationdeveloping new innovative lines of new products and new technologies in the Company’s new natural food business.

products.

-23-
(In thousands)Three Months EndedChangeNine Months EndedChange
February 28, 2021February 23, 2020Amount%February 28, 2021February 23, 2020Amount%
Curation Foods$1,052 $1,240 $(188)(15)%$3,123 $4,047 $(924)(23)%
Lifecore1,510 1,507 3— %4,520 4,295 225%
Other— — — — %$— $48 (48)(100)%
Total R&D$2,562 $2,747 $(185)(7)%$7,643 $8,390 $(747)(9)%

Table of Contents

The Company’s ability to compete successfully depends heavily upon its ability to ensure a continual and timely flow of innovative and competitive products, services, and technologies to the marketplace. The Company continues to develop new products and to expand the range of its product offerings through R&D.

R&D expenses include expenditures for new product and manufacturing process innovation, or a significant improvement to an existing product or process, which consist of expenses incurred in performing R&D activities, including compensation and benefits for R&D employees, facilities expenses, overhead expenses, cost of laboratory and innovation supplies, third-party formulation expenses, fees paid to contract research organizations and other consultants, stock-based compensation for R&D employees, and other outside expenses.

The increasedecrease in R&D expenses for the three and sixnine months ended November 26, 2017February 28, 2021, compared to the same periods last year, was primarily due to a significant increase inlower professional service expenses related to brand restage initiatives and new product development in the salad kit and avocado products product lines at Curation Foods which took place during fiscal year 2020, and decreases in our Other segment primarily due to discontinuation of R&D activities at ApioCorporate. These decreases were partially offset by higher salary and benefits expenses at Lifecore driven primarily from the hiring of a VP of Innovation and R&D during the fourth quarter of fiscal year 2017 and the subsequent staff hiring in that department, coupled withby an increase in product development activities in Apio’s marketing department.

increased headcount.

Selling, General, and Administrative

Selling, general and administrative (“SG&A”)

SG&A expenses consist primarily of sales and marketing expenses associated with Landec’s product sales and services, business development expenses, and staff and administrative expenses.


(In thousands)Three Months EndedChangeNine Months EndedChange
February 28, 2021February 23, 2020Amount%February 28, 2021February 23, 2020Amount%
Curation Foods$9,509 $10,260 $(751)(7)%$29,612 $34,923 $(5,311)(15)%
Lifecore2,233 1,958 27514 %6,075 5,855 220 %
Other3,478 6,565 (3,087)(47)%13,540 13,222 318 %
Total SG&A$15,220 $18,783 $(3,563)(19)%$49,227 $54,000 $(4,773)(9)%

The decrease in total SG&A expenses for the three and six months ended November 26, 2017February 28, 2021, compared to the same periodsperiod last year, was due to a $3.1 million decrease in SG&A at Apio as a result of (1)our Other segment due to a decrease in marketing expenses, (2) legal fees from compliance and legal settlement costs incurred during the three and six months ended November 27, 2016 of last year from the labor-related lawsuits settled during fiscal year 2017 and (3)other litigation matters, including a reversal ofrelated insurance recovery, combined with a portion of the annual bonus at the end of the second quarter of fiscal 2018$0.8 million decrease in our Curation Foods business primarily due to actual year-to-date results beingcost savings driven by our restructuring efforts associated with Project SWIFT and lower than budget. salary expenses compared to the same period last year.

The decrease at Apio was partially offset by an increase in SG&A expenses in Other resulting from an increase in stock-based compensation from equity grants during the first six months of fiscal 2018, from new business development activities and from $343,000 and $729,000, respectively, oftotal SG&A expenses for the three and sixnine months ended November 26, 2017 incurredFebruary 28, 2021, compared to the same period last year, was due to a $5.3 million decrease in our Curation Foods business primarily due to cost savings driven by O Olive which was acquired on March 1, 2017. These increases in SG&A in Other was partially offset by a $500,000 reduction in SG&A from a reduction in the contingent consideration liabilityour restructuring efforts associated with Project SWIFT and lower salary expenses compared to the O Olive acquisition.

Other (same period last year. The decrease was also partly due to a reserve reported in thousands)fiscal year 2020 for the note receivable from Pacific Harvest.


-30-

Table of Contents
Other:

  

Three Months Ended

  

Six Months Ended

 
  

November 26, 2017

  

November 27, 2016

  

Change

  

November 26, 2017

  

November 27, 2016

  

Change

 

Dividend Income

 $412  $412   0% $825  $825   0%

Interest Income

  42   4   950%  74   7   957%

Interest Expense

  (480)  (380)  26%  (884)  (1,032)  (14%)

Loss on Debt Refinancing

     (1,233) 

N/M

      (1,223) 

N/M

 

Other Income

  1,300     

N/M

   2,200     

N/M

 

Income Tax Expense

  (207)  (693)  (70%)  (1,458)  (2,582)  (44%)

Non-controlling Interest Expense

  (26)  (48)  (46%)  (92)  (81)  14%

(In thousands)Three Months EndedChangeNine Months EndedChange
February 28, 2021February 23, 2020Amount%February 28, 2021February 23, 2020Amount%
Dividend Income$281 $281 $— — %$844 $843 $—%
Interest Income$13 $46 $(33)(72)%$31 $96 $(65)(68)%
Interest Expense$(4,178)$(2,211)$(1,967)89 %$(10,326)$(6,455)$(3,871)60 %
Loss on Debt Refinancing$(1,110)$— $(1,110)(100)%$(1,110)$— $(1,110)(100)%
Other Income (Expense)$72 $67 $N/M$(11,736)$61 $(11,797)N/M
Income Tax Benefit$217 $5,310 $(5,093)(96)%$7,226 $7,840 $(614)(8)%

Dividend Income

Dividend income is derived from the dividends accrued on the Company’s $22$15.0 million seniorSenior A preferred stock investment in Windset, which yields a cash dividend of 7.5% annually. There was no change in dividend income for the three and six months ended November 26, 2017 compared to the same periods last year.


Interest Income

The increasedecrease in interest income for the three and sixnine months ended November 26, 2017February 28, 2021, compared to the same periods last year, was not significant.


Interest Expense

The increase in interest expense for the three and nine months ended November 26, 2017February 28, 2021, compared to the same period last year, was primarily due to lower capitalizationthe result of (i) an increased interest for long-term capital projects during the second quarter of fiscal year 2018 compared to the second quarter of fiscal year 2017.

-24-

The decrease in interest expense for the six months ended November 26, 2017 compared to the same period last year was primarilyrate, due to the Company's increased Total Leverage Ratio (as defined Credit Agreement), combined with our debt refinancing ofin December 2020 at higher interest rates, (ii) an increase in deferred financing costs from those incurred in connection with the Company’sCompany's amendments to the Credit Agreement since November 24, 2019 combined with our debt during the second quarter of fiscal year 2017 which resultedrefinancing in a lower average interest rate on the Company’sDecember 2020, and (iii) an increase in total outstanding debt since then.

at February 28, 2021 compared to February 23, 2020.

Loss on Debt Refinancing

The loss on debt refinancing for the three and six months ended November 27, 2016 wasprimarily due to the one-timea write-off of unamortized debt issuance costs and earlyin connection with the Company refinancing its debt extinguishment prepayment penalties on the Company’s then existing debt as of September 23, 2016.

in December 2020.

Other Income

(Expense)

The increase in other income (expense) for the three and six months ended November 26, 2017 compared to the same periods last year was a result of the change in the fair value of the Company’s investment in Windset which increased $1.3 million and $2.2 million, respectively, for the three and six months ended November 26, 2017.

Income Taxes

The decrease in the income tax expense during the three and six months ended November 26, 2017 compared to the same periods last year was due to a 65% and 43%, respectively, decrease in pre-tax income for the three and six months ended November 26, 2017 compared to the same periods last year.

Non-controlling Interest

The non-controlling interest consists of the limited partners’ equity interest in the net income of Apio Cooling, LP. The change in the non-controlling interest for the three and six months ended November 26, 2017February 28, 2021, compared to the same periods last year, was not significant.

The decrease in other income (expense) for the nine months ended February 28, 2021, compared to the same periods last year, was primarily a result of the decrease in fair value of our investment in Windset of $11.8 million.

Income Taxes

The effective tax rate for the three and nine months ended February 28, 2021 was higher than the statutory federal income tax rate of 21% primarily due to the income tax benefit on the increased forecasted losses, the generation of federal & state R&D credits and impact of states taxes, partially offset by the movement of the valuation allowance recorded against certain deferred tax assets.

Liquidity and Capital Resources


As of November 26, 2017,February 28, 2021, the Company had cash and cash equivalents of $4.4$2.2 million, a net decreaseincrease of $1.0$1.9 million from $5.4$0.6 million as of May 28, 2017.

31, 2020. Based on all available current information, the Company believes the combination of its cash and cash equivalents and availability under the New Credit Agreements (defined below) will be sufficient to support its operations for at least the next twelve months.

-31-

Table of Contents
Cash Flow from Operating Activities

Landec generated

Net cash provided by operating activities during the nine months ended February 28, 2021 was $10.6 million, compared to $4.3 million of net cash from operating activities during the six months ended November 26, 2017, compared to $5.5 million of net cash generated fromused in operating activities for the same period last year.nine months ended February 23, 2020. The primary sources of net cash fromprovided by operating activities during the sixnine months ended November 26, 2017February 28, 2021 were from (1) $2.7$18.5 million of net income, (2) $8.0 million of depreciation/depreciation and amortization, and stock based compensation expenses,expense, and loss on debt refinancing, (2) an $11.8 million decrease in the Company's estimated fair value of Windset due to changes in the financial assumptions relating to EBITDA, non-productive assets, and debt levels, (3) a $1.4$9.5 million net increasedecrease in deferred tax liabilities.working capital, and (4) $7.9 million from the non-cash restructuring and impairment of assets charges. These sources of cash were offset by (1) a $2.2$29.8 million increasenet loss, and (2) a $7.3 million reduction in the fair market value of the Company’s Windset investment, a non-cash increase to income and from a net increase of $5.4 million in working capital.

deferred taxes.

The primary factors which increased workingfor the decrease in working capital during the first sixnine months of fiscal year 2018ended February 28, 2021, were (1) a $9.3 million increase in accounts receivable due to a $6.5 million increase in accounts receivable at Apio due to sales in November 2017 being $5.9 million higher than May 2017 and a $3.0 million increase in accounts receivable at Lifecore due to sales in November 2017 being $1.5 million higher than May 2017 and the timing of collections at the end of the second quarter of fiscal year 2017, (2) a $5.5 million increase in inventories due primarily to a $2.4 million increase at Apio from an increase in raw materials for expected increases in salad sales during the third quarter and from a $2.7 million increase at Lifecore as it builds its inventory for a  large volume of shipments during the third quarter of fiscal year 2018, and (3) a $2.3 million decrease in other accrued liabilities due to legal settlement payments made during the first six months of fiscal year 2018. The increases in working capital were partially offset by a $11.6$6.4 million increase in accounts payable due primarily to the timing of payments, (2) a $10.8$6.2 million increase at Apiodecrease in accounts receivable due to the timing of customer payment receipts, and (3) a $8.6$3.2 million increase in cost of sales in November 2017 comparedother accrued liabilities due primarily to May of 2017 and from the timing of payments.  

payment, partially offset by a $10.5 million increase in inventory driven by our strategy to build inventory during the peak avocado season.

Cash Flow from Investing Activities

Net cash provided by investing activities during the nine months ended February 28, 2021 was $1.5 million compared to $19.3 million used in investing activities for the six months ended November 26, 2017 was $9.5 million compared to $4.7 million for the same period last year. The primary uses ofNet cash inprovided by investing activities during the first sixnine months ended February 28, 2021, was primarily due to the net proceeds of fiscal year 2018 were for$12.9 million related to the sale of the Company's Ontario, California and Hanover, Pennsylvania facilities, offset by the purchase of $7.4$11.4 million of equipment primarily to support the growth of the Apio Packaged Fresh VegetablesCompany’s Curation Foods and Lifecore businesses and from the issuance of a $2.1 million note receivable.

businesses.
-25-

Table of Contents

Cash Flow from Financing Activities

Net cash provided by financing activities for the six months ended November 26, 2017 was $4.1 million compared to net cash used in financing activities of $8.1during the nine months ended February 28, 2021 was $10.4 million compared to $25.0 million provided by financing activities for the same period last year. The net cash provided byused in financing activities during the first sixnine months of fiscal year 2018ended February 28, 2021, was primarily due to $7.0the $9.6 million payment of net borrowings under the Company’s line of credit. These borrowings were partially offset by $2.5 million of payments on the Company’s long-term debt.

debt issuance costs.

Capital Expenditures

During the sixnine months ended November 26, 2017,February 28, 2021, Landec incurred $11.4 million of capital expenditures, which was primarily represented by facility expansions and purchased equipment to support the growth of the Apio Packaged Fresh VegetablesLifecore and Lifecore businesses. These expenditures represented the majority of the $7.4 million ofCuration Foods businesses, compared to capital expenditures inof $22.1 million for the period.

nine months ended February 23, 2020. During the nine months ended February 28, 2021, capital expenditures for Lifecore and Curation Foods were $6.9 million and $4.5 million, respectively.

Debt

On September 23, 2016, the Company entered into a Credit Agreement (the "Credit Agreement") with JPMorgan, BMO Harris Bank N.A. ("BMO"), and City National Bank, as lenders (collectively, the Lenders”“Lenders”), and JPMorgan as administrative agent, pursuant to which the Lenders provided the Company with a $100$100.0 million revolving line of credit (the “Revolver”) and a $50$50.0 million term loan facility (the “Term Loan”), guaranteed by each of the Company’s direct and indirect subsidiaries and secured by substantially all of the Company’s assets, with the exception of the Company’s investment in Windset.

On October 25, 2019, the Company entered into the Sixth Amendment to the Credit Agreement, which among other things, increased the Term Loan to $120.0 million.

On July 15, 2020, the Company entered into the Eighth Amendment to the Credit Agreement (the “Eighth Amendment”), which among other things, (i) modified the definition of EBITDA to increase the limit on permitted exclusions for certain unusual, extraordinary or one-time cash items for each fiscal quarter ending on or after February 28, 2021, to a maximum of 20% of EBITDA, and (ii) restricted the Company from making Capital Expenditures over certain thresholds. Interest continues to be based on the Company’s Total Leverage Ratio, at a revised per annum Applicable Rate of either (i) the prime rate plus a spread of between 0.75% and 3.50% or (ii) the Eurodollar rate plus a spread of between 1.75% and 4.50%, plus, in each case, a commitment fee, as applicable, of between 0.15% and 0.55%, as further described in the Eighth Amendment.
-32-

Table of Contents
Both the Revolver and the Term Loan were scheduled to mature in five years (onon September 23, 2021),2021, with the Term Loan providing forrequiring quarterly principal payments of $1.25$3.0 million and the remainder continuing to be due at maturity. The Credit Agreement contained customary financial covenants and events of default under which the obligation could be accelerated and/or the interest rate increased.
On December 31, 2020, the Company refinanced its existing Term Loan and Revolver by entering into two separate Credit Agreements (the "New Credit Agreements") with BMO and Goldman Sachs Specialty Lending Group, L.P. (“Goldman”) and Guggenheim Credit Services, LLC ("Guggenheim"), as lenders (collectively, the “Refinance Lenders”). Pursuant to the credit agreement related to the revolving credit facility, BMO has provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $75.0 million revolving line of credit (the “Refinance Revolver”) and serves as administrative agent of the Refinance Revolver. Pursuant to the credit agreement related to the term loan, Goldman and Guggenheim have provided the Company, Curation Foods and Lifecore, as co-borrowers, with an up to $170.0 million term loan facility (split equally between Goldman and Guggenheim) (the “Refinance Term Loan”) and Goldman will serve as administrative agent of the Refinance Term Loan. The Refinance Revolver and Refinance Term Loan are guaranteed, and secured by, substantially all of the Company’s and the Company's direct and indirect subsidiaries' assets.

The Refinance Term Loan matures on December 31, 2025. The Refinance Revolver matures on December 31, 2025 or, if the Refinance Term Loan remains outstanding on such date, ninety (90) days prior to the maturity date of the Refinance Term Loan (on October 2, 2025).

The Refinance Term Loan provides for principal payments by the Company of 5% per annum, payable quarterly in arrears in equal installments, commencing December 1, 2016,on March 30, 2023, with the remainder due at maturity.

See Note 7 – Debtmaturity.


Interest on the Refinance Revolver is based upon the Company’s average availability, at a per annum rate of either (i) LIBOR rate plus a spread of between 2.00% and 2.50% or (ii) base rate plus a spread of between 1.00% and 1.50%, plus a commitment fee, as applicable, of 0.375%. Interest on the Refinance Term Loan is at a per annum rate based on either (i) the base rate plus a spread of 7.50% or (ii) the LIBOR rate plus a spread of 8.50%.

The New Credit Agreements provide the Company the right to increase the revolver commitments under the Refinance Revolver, subject to the satisfaction of certain conditions (including consent from BMO), by obtaining additional commitments from either BMO or another lending institution at an amount of up to $15.0 million.

The New Credit Agreements contains customary financial covenants and events of default under which the obligations thereunder could be accelerated and/or the interest rate increased in specified circumstances.

In connection with the New Credit Agreements, the Company incurred debt issuance costs from the lender and third-parties of $9.3 million.

Concurrent with the close of the Notes to Consolidated Financial Statements for further discussionNew Credit Agreements, the Company repaid all outstanding borrowings under the current Credit Agreement, and terminated the Credit Agreement. In connection with the repayment of borrowings under the Credit Agreement, the Company recognized a loss in its third quarter of fiscal year 2021 of $1.1 million, as a result of the Company’snon-cash write-off of unamortized debt arrangements.

Landec believes that its cash from operations, alongissuance costs related to the refinancing under the New Credit Agreements.


As of February 28, 2021, $41.0 million was outstanding on the Refinance Revolver and $145.1 million, net of debt issuance costs, was outstanding on the Refinance Term Loan, at interest rates of 2.75% and 9.5%, respectively. As of February 28, 2021, the Company was in compliance with existing cashall financial covenants and cash equivalents will be sufficient to finance its operational and capital requirements for at leasthad no events of default under the next twelve months.

New Credit Agreements.


Item 3.    Quantitative and Qualitative Disclosures AboutAbout Market Risk

There have been no material changes to the Company's market risk duringinformation provided under Item 7A. "Quantitative and Qualitative Disclosures About Market Risk" which is included and described in the first six months ofForm 10-K for the fiscal year 2018.

ended May 31, 2020 filed with the SEC on August 14, 2020.




-33-

Table of Contents
Item 4.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management

As of February 28, 2021, our management evaluated, with participation of theour Chief Executive Officer and theour Chief Financial Officer, the effectiveness of the Company’sour disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q.procedures. Based on this evaluation, theour Chief Executive Officer and our Chief Financial Officer have concluded that the Company’s disclosure controls and procedures are effective in ensuring that information required to be disclosed in reports filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission,SEC, and are effective in providing reasonable assurance that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controlscontrol over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the fiscal quarter ended November 26, 2017February 28, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controlscontrol over financial reporting.

-26-
-34-

Table of Contents

Part

PART II. Other Information

OTHER INFORMATION

Item 1.    LegalProceedings

In the ordinary course of business, the Company is involved in various legal proceedings and claims.

The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred For further discussion, see the disclosures contained in Note 1 - Organization, Basis of Presentation, and the amountSummary of the loss can be reasonably estimated. These provisionsSignificant Accounting Policies - Legal Contingencies, which are reviewed at least each fiscal quarter and adjusted to reflect the impacts of negotiations, estimate settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.

Apio has been the target of a union organizing campaign which has included two unsuccessful attempts to unionize Apio's Guadalupe, California processing plant. The campaign has involved a union and over 100 former and current employees of Pacific Harvest, Inc. and Rancho Harvest, Inc. (collectively "Pacific Harvest"), Apio's labor contractors at its Guadalupe, California processing facility, bringing legal actions before various state and federal agencies, the California Superior Court, and initiating over 100 individual arbitrations against Apio and Pacific Harvest.

The legal actions consist of three main types of claims: (1) Unfair Labor Practice claims ("ULPs") before the National Labor Relations Board (“NLRB”), (2) discrimination/wrongful termination claims before state and federal agencies and in individual arbitrations, and (3) wage and hour claims as part of two Private Attorney General Act (“PAGA”) cases in state court and in over 100 individual arbitrations.

A settlement of the ULPs among the union, Apio, and Pacific Harvest that were pending before the NLRB was approved on December 27, 2016 for $310,000. Apio was responsible for half of this settlement, or $155,000. On May 5, 2017, the parties to the remaining actions executed a settlement agreement concerning the discrimination/wrongful termination claims and the wage and hour claims which covers all non-exempt employees of Pacific Harvest working at Apio's Guadalupe, California processing facility from September 2011 through the settlement date. Under the settlement agreement, the plaintiffs are to be paid $6.0 million in three installments: $2.4 million, which was paid on July 3, 2017, $1.8 million which was paid on November 22, 2017 and $1.8 million which is due in July 2018. The Company and Pacific Harvest have each agreed to pay one half of the settlement payments. The Company paid the entire first two installments of $4.2 million and will be reimbursedincorporated herein by Pacific Harvest for its $2.1 million portion which is included in Other assets in the accompanying Consolidated Balance Sheets. This receivable will be repaid through monthly payments until fully paid, which the Company expects to occur by December 2020. The Company and Pacific Harvest will both make one half of the third installment in July 2018. The Company’s recourse against non-payment by Pacific Harvest is its security interest in assets owned by Pacific Harvest.

As of November 26, 2017 and May 28, 2017, the Company had accrued $1.0 million and $3.2 million, respectively, related to these actions, which is included in Other accrued liabilities in the accompanying Consolidated Balance Sheets.

reference.

Item 1A.    Risk Factors

Our estimated annual effective tax rate may be subject to further uncertainty due to

You should carefully consider the recent changes in U.S. tax rates and tax laws. Other than this item, there have been no significant changes to the Company's risk factors which are included andrisks described in the Form10-KItem 1A, Risk Factors, of our Annual Report on Form 10-K for the fiscal year ended May 31, 2020, as supplemented by our Quarterly Report on Form 10-Q for the fiscal period ended February 28, 2017 filed with2021, as our business, financial condition and results of operations could be adversely affected by any of the Securitiesrisks and Exchange Commissionuncertainties described therein and herein. There have been no material changes to our risk factors as previously disclosed in our Annual Report on August 10, 2017.

Form 10-K for the fiscal year ended May 31, 2020, as supplemented by our Quarterly Report on Form 10-Q for the fiscal period ended February 28, 2021.


Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities or shares repurchased by the Company during the fiscal quarter ended on November 26, 2017.

None.

Item 3.    Defaults Upon Senior Securities

None.

None.

Item 4.    Mine Safety Disclosures

Not applicable

applicable.

Item 5.    Other Information

None.


-27-
-35-

Table of Contents

Item 6.    Exhibits


Exhibit
Number

Exhibit Title

31.1+

Exhibit
Number

Exhibit Title

31.2+

32.1+

32.2+

101.INS+

XBRL Instance

101.INS**

101.SCH+

XBRL Instance

101.SCH**

XBRL Taxonomy Extension Schema

101.CAL+

101.CAL**

XBRL Taxonomy Extension Calculation

101.DEF+

101.DEF**

XBRL Taxonomy Extension Definition

101.LAB+

101.LAB**

XBRL Taxonomy Extension Labels

101.PRE+

101.PRE**

XBRL Taxonomy Extension Presentation

+

Filed herewith.

+

*

FiledFurnished herewith.

** XBRL

information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.


-28-
-36-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrantregistrant has duly caused this Reportreport to be signed on its behalf by the undersigned thereunto duly authorized.


LANDEC CORPORATION

LANDEC CORPORATION

By:

/s/ Gregory S. Skinner

By:

Gregory S. Skinner

/s/ John Morberg

Vice President Finance and John Morberg

Chief Financial Officer

(Principal Financial and Accounting Officer)

Date:     January 5, 2018

-29-

    April 8, 2021

-37-